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AAO Acute aortic occlusion
ABI Ankle brachial pressure index
AC Anticoagulation
AF Atrial fibrillation
ALI Acute limb ischaemia
APTT Activated partial thromboplastin time
ASA Acetylsalicylic acid
CDT Catheter directed thrombolysis
CE-MRA Contrast enhanced magnetic resonance
angiography
CI Confidence interval
CK Creatine kinase. (This is the same enzyme as
creatine phosphokinase, often abbreviated
CPK in older literature, and in some
countries.)
COMPASS Cardiovascular Outcomes for People Using
Anticoagulation Strategies
CRP C reactive protein
CS Compartment syndrome
CTA Computed tomography angiography
DOAC Direct oral anticoagulants
DSA Digital subtraction angiography
DUS Duplex ultrasound
ECG Electrocardiogram
ECMO Extracorporeal membrane oxygenation
ESC Eurpean Society of Cardiology
ESVS European Society for Vascular Surgery
EVAR Endovascular aneurysm repair
HR Hazard ratio
IRI Ischaemia reperfusion injury
IU International unit
LMWH Low molecular weight heparin
MALE Major adverse limb events
NHDS National Hospital Discharge Survey
OR Odds ratio
PA Popliteal artery aneurysm
PAD Peripheral artery disease
PMT Pharmacomechanical thrombolysis
PTA Percutaneous transluminal angioplasty
RCT Randomised controlled trial
RR Relative risk
rtPA Recombinant tissue plasminogen activator
STILE Surgery vs. Thrombolysis for Ischaemia of the
Lower Extremity
TOPAS Thrombolysis or Peripheral Arterial Surgery
UFH Unfractionated heparin
VQI Vascular Quality Initiative
WC Writing committee1. INTRODUCTION expertise). To further underline this supportive character of the1.1. Purpose
The European Society for Vascular Surgery (ESVS) has developed
guidelines for treating patients with acute limb ischaemia (ALI).
The focus on the guidelines is on lower limb acute ischaemia;
however recommendations are also made on acute upper limb
ischaemia. The term acute leg ischaemia is not used, in order to
avoid confusion, as the same abbreviation, “ALI”, may be used.
These guidelineswill provide guidance for emergencyphysicians;
vascular, cardiovascular and general surgeons; angiologists;
interventional radiologists; and radiologists. The target popula-
tion comprises patients with acute lower and/or upper limb
ischaemia. The guidelines, which are developed by specialists in
the field, promote a high standard of care (based on evidence,
whenever available). Guidelines should not be viewed as a legal
standardofcare.Thisdocument is a guiding support, and thecare
given to a patient will always be dependent on the individual
(symptom variability, comorbidities, age, level of activity), and
treatment setting (techniques available, local circumstances, andGuidelines, non-European reviewers were invited to review the
document, so that it could serve doctors treating patients glob-
ally. This is also the rationale behind the decision to publish all
ESVS Guidelines as free to download, and why the ESVS Guide-
lines app also can be downloaded free of charge from the ESVS
website (www.esvs.org).1.2. Methodology
1.2.1. Writing Committee. Members of the Writing Com-
mittee (WC) were selected by the ESVS to represent clinicians
involved in the treatmentofALI and included vascular surgeons
and interventional radiologists. Members of the WC have
provided disclosure statements regarding all relationships that
might be perceived as real or potential sources of conflicts of
interest.These are filed and available from ESVS headquarters.
Members of the WC received no financial support from any
pharmaceutical, device, or surgical industry to develop these
guidelines.The ESVS Guideline Committee was responsible for
Weight of evidence/opinion is in favour of usefulness/efficacy.
Usefulness/efficacy is less well established by evidence/opinion.
Evidence or general agreement that the given treatment or
procedure is not useful/effective, and in some cases may be harmful.
Class IIb
Class IIa
Class II
Class III
Class I
Classes of
recommendation
Definition
Evidence and/or general agreement that a given 
treatment or procedure is beneficial, useful, and effective.
Conflicting evidence and/or a divergence of opinion about
the usefulness/efficacy of the given treatment or procedure.
Figure 2. Classes of recommendation.
176 Martin Björck et al.undertaking the review process. The final version was checked
and approved by the WC and the Guideline Committee.
1.2.2. Definition of clinically relevant issues. The WC held
an introductory meeting on 13/14 June 2018 in Uppsala,
Sweden, where the list of topics and author tasks were
determined. After the first draft was completed and inter-
nally reviewed, the WC met again on 14/15 January 2019 in
Hamburg, Germany, to review and approve the wording of
each recommendation. The Guidelines then underwent
external reviews, and the final version of the document was
approved on July 30th, 2019.
1.2.3. Literature search. Members of the WC agreed on a
common systematic literature search strategy for each of the
assigned chapters. The literature search of articles published
from 1 January 1990, published in English, was performed in
the PubMed, Embase, Cardiosource Clinical Trials Database,
and Cochrane Library databases up to 31 July 2018.The search
was performed with the help of an information specialist (a
clinical librarian). Reference checking andmanual searching by
the members of the WC added other relevant literature. In
all, 6 549 unique abstracts were retrieved after duplicates
were removed. The detailed literature search is described in
Appendix S1 (see Supplementary Material).
Selection of the literature was based on the information
provided in the titles and abstracts of the retrieved studies.
Only peer reviewed published literature and studies with
predefined outcomes were considered. The selection process
followed the pyramid of evidence, with aggregated evidence
at the top of the pyramid (systematic reviews, meta-analyses),
followed by randomised controlled trials (RCTs), and, finally,
observational studies. Single case reports, abstracts, and
in vitro studies were excluded, leaving expert opinion at the
bottom of the pyramid. Articles published after the search
date or in another languagewere only included if theywere of
paramount importance to these guidelines. After the second
external review the members of the WC were asked to
perform a second literature search within their area of re-
sponsibility to see if any important publications had been
published between 31 July 2018 and 21 June 2019.
1.2.4. Evidence and recommendations criteria. The Euro-
pean Society of Cardiology (ESC) system was used for
grading evidence and recommendations. A, B, or C reflects
the level of current evidence (Fig. 1) and the strength of
each recommendation was then determined to be either
class I, IIa, IIb, or III (Fig. 2).
1.2.5. The revision process. The guidelines document
underwent revision by members of the ESVS GuidelinesLevel of evidence A Data derived from multiple randomised clinical trials or 
meta-analyses.
Level of evidence B Data derived from a single randomised clinical trial or 
large non-randomised studies.
Level of evidence C Consensus of opinion of the experts and/or small studies,
retrospective studies, and registries.   
Figure 1. Levels of evidence.Committee, and by external experts in the field. Each
draft was revised according to the reviewers’ sugges-
tions and the final document was submitted to the
European Journal of Vascular and Endovascular Surgery
(EJVES) and the ESVS Guidelines Committee on 4 July
2019.1.3. Terminology and definitions
ALI is characterised by a sudden decrease in arterial
perfusion of the limb, with a potential threat to the survival
of the limb, requiring urgent evaluation and management.1
ALI is considered when the symptom duration is less than
two weeks.2,3 A symptom duration of greater than two
weeks is usually considered to represent chronic limb
ischaemia and is covered by other guidelines.4,5
The most common causes of ALI are embolism, throm-
bosis of native arteries or reconstructions, peripheral arte-
rial aneurysm, dissection, and traumatic arterial injury. The
ischaemia is graded clinically according to the Rutherford
ALI classification system (see Table 2).2 Assessment de-
termines whether the limb is viable or irreversibly damaged.
The distinction between grade IIa and IIb, and between
grade IIb and III, can sometimes be challenging. Prompt
diagnosis and revascularisation by means of catheter based
thrombolysis and/or thrombaspiration or by open surgery
reduces the risk of limb loss and death. Primary amputation
is recommended in patients with irreversible (Class III)
ischaemia. Despite urgent revascularisation, mortality and
major amputation rates are high (for details see section 5,
Registries and Quality Improvement).
1.3.1. Areas not covered by these guidelines. The general
rule for ESVS guidelines is to avoid covering groups of pa-
tients in multiple guidelines, as that may result in contra-
dictions. For this reason, the following groups of patients
are not covered by these guidelines. (i) Aortic dissection
may result in ALI, most often as a result of compression of
the true lumen or dynamic / static obstruction of flow in
one or both of the iliac arteries. This condition is covered by
the Management of Descending Thoracic Aorta Diseases:
Clinical Practice Guidelines of the ESVS.6 (ii) ALI may occur
as a complication of aortic surgery, but that issue is covered
by the ESVS 2019 Clinical Practice Guidelines on the Man-
agement of Abdominal Aorto-iliac Artery Aneurysms.7 (iii)
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Guidelines on Vascular Trauma / Injuries. Thus, ALI sec-
ondary to trauma (iatrogenic or not) is not covered by these
guidelines, except when discussing ALI in children (section
8, ALI in Children). (iv) Upper limb ALI is covered in section 7
(Diagnosis and Treatment of Upper Limb Acute Ischaemia),
but treatment of patients who develop this condition dur-
ing renal replacement therapy is covered by the Vascular
Access 2018 Clinical Practice Guidelines of the ESVS.8 (v)
Ischaemia may also develop secondary to deep venous
thrombosis, and secondary low arterial blood flow, but this
condition (phlegmasia cerulea dolens) is covered by the
2015 ESVS Venous Guidelines.9 (vi) Blue toe syndrome,
when emboli lodge in the arteries of the toes (or fingers;
often referred to as endarteries, as they lack collaterals) is
often associated with great pain but is not covered by these
guidelines, as the condition does not result in limb
ischaemia. When this condition is suspected it is important
to identify the source of embolism.4 (vii) A number of un-
common causes of ALI are only mentioned for the sake of
differential diagnosis (Table 1). The management of these
rare diseases can be studied in textbooks.1.4. Historical notes
An invited editorial on the history of the treatment of ALI is
published together with these Guidelines: “Where we have
come from: a short history of surgery for ALI”.131.5. Epidemiology
The true incidence of ALI is largely unknown owing to
heterogeneous forms of presentation and treatment.
Frequently, epidemiological studies include both ALI and
chronic limb ischaemia, without clear differentiation. Also,
there may be significant geographical variations due to
ethnicity, accessibility, and quality of health care; most of
the data on which these guidelines are based are fromTable 1. Uncommon causes of acute limb ischaemia10e12
Cause Pathology
Vasculitis Inflammation of the arteries
Popliteal entrapment syndrome The popliteal artery is compressed by
tendon during plantar flexion
Adventitial cystic disease Cyst in the vessel wall, occluding blo
Paradoxical embolism Atrial septal defect, venous thrombo-
(often with pulmonary hypertension)
Tumour embolism Tissue like embolic material
Acute compartment syndrome Swelling of tissues within fascial com
(especially the anterior compartment
compressing arteries
Foreign body embolisation Gangrene in multiple fingers or toes,
associated with infection or intraveno
Thrombophilia Arterial thrombosis without risk facto
Low cardiac output syndromes Low blood flow to the extremities, w
devices. Common causes: hypotension
and sepsisWestern Europe and North America. Exceptionally, a pub-
lication reported on a Chinese population who underwent
thrombolysis for ALI, with similar results to those reported
from Europe and North America.14 The EUCLID study
(Examining Use of Ticagrelor in Peripheral Artery Disease)
was a global RCT on ticagrelor treatment of patients with
peripheral artery disease (PAD) and recruited 13 885 pa-
tients from 28 countries and 811 sites. They reported on
two interesting subgroups: 642 (4.6%) patients who had
critical limb ischaemia at baseline,3 and 232 (1.7%) who
developed ALI (0.8 per 100 patient years).15 Risk factors for
the development of ALI in this cohort, with mainly benign
chronic limb ischaemia, were previous peripheral revascu-
larisation, atrial fibrillation (AF), and lower ankle brachial
pressure index (ABI).
Over the last century, there has been a general shift in
aetiology from embolisation due to rheumatic or congenital
valve disease in relatively young patients; to embolisation
due to cardiac dysrhythmia; or in situ thrombosis in elderly
patients.16,17 It is important to note that ALI caused by
native artery thrombosis or embolisation into an athero-
sclerotic vascular bed has increased in incidence, which has
important implications for treatment.13 Validation of charts
revealed three distinct categories of ALI: (i) lower limb
arterial thrombo-embolism; (ii) acute exacerbation of
chronic limb ischaemia; and (iii) iatrogenic ALI after revas-
cularisation procedures. Approximately 70% of patients
presented within two weeks of symptom onset, whereas
30% of patients presented with symptoms lasting more
than two weeks. The cause of embolisation is usually
attributed to AF or left ventricular mural thrombi after
acute myocardial infarction, whereas acute thrombotic oc-
clusions occur in individuals with a high atherosclerotic
burden.18 Lower extremity embolisation due to aortic
thrombi is a well known source of embolisation, and may be
caused by manipulation of devices during endovascular
repair of abdominal aortic aneurysm.19Signs to look for
Bilateral disease. Systemic symptoms (e.g., fever).
Signs of connective tissue disease.
muscle or Young active patient, no atherosclerotic risk factors.
History of claudication pain.
od flow Acute arterial thrombosis (usually popliteal) in a
young person. No atherosclerotic risk factors.
embolism Venous thrombo-embolism, cardiac bruit, and
pulmonary embolism
Signs of tumour or malignancy (usually advanced)
in heart or lung
partment
of leg)
History of revascularisation or prolonged surgery.
Pain on passive movement
often
us drug use
Intravenous drug users
rs Young patients, often with a family history
orsened by
, shock,
Patients with severe cardiac failure, intra-aortic
pump devices, extracorporeal membrane
oxygenation (ECMO)
Table 2. Clinical categories of acute limb ischaemia according to Rutherford2
Grade Category Sensory loss Motor deficit Prognosis Doppler signals
Arterial Venous
I Viable None None No immediate threat Audible Audible
IIA Marginally threatened None or minimal (toes) None Salvageable if promptly
treated
Inaudible* Audible
IIB Immediately threatened More than toes Mild/moderate Salvageable if promptly
revascularised
Inaudible Audible
III Irreversible Profound, anaesthetic Profound, paralysis
(rigor*)
Major tissue loss amputation.
Permanent nerve damage
inevitable
Inaudible Inaudible
This is an identical replica of the table in the 1997 publication by Rutherford et al.,2 with the exception of the asterisks (*).
* In the original 1997 classification it was stated that arterial Doppler sounds are never present in Stage IIA, and that rigor (mortis) is always
present in Stage III. However, it is the opinion of the Writing Committee that exceptions to these rules do exist, and a slight modification of
the Rutherford classification from 1997 may be appropriate in the future.
178 Martin Björck et al.Historical data from Sweden and the UK have suggested
an incidence of 3 e 14 per 100 000 person years, with a
large majority of individuals being >80 years of age.20e23
The largest contemporary epidemiological analysis of
treatment of ALI used the National Hospital Discharge
Survey (NHDS, USA).18 Some 1 092 811 hospital admissions
from 1988 to 1997 were for acute arterial embolism or
thrombosis of the lower limb; this was reduced to 670 704
from 1998 to 2007, implying a decrease in the incidence of
arterial embolisation or thrombosis from 42.4 per 100 000
person years from 1988 to 1997 to 23.3 per 100 000 person
years from 1998 to 2007. Hospital mortality also decreased
from 8.3% to 6.3%. Unfortunately, this publication did not
differentiate between embolism and thrombosis, and
bypass thrombosis was excluded.
In another epidemiological study of treatment of ALI in
the Medicare population of the USA between the years
1998 and 2009, the incidence of ALI related hospital ad-
missions decreased from 45.7 to 26.0 per 100 000 person
years.24 The number of patients undergoing open revascu-
larisation was reduced from 57.1% to 52.6%, while endo-
vascular procedures were doubled, from 15.0% to 33.1%.
Hospital mortality decreased from 12.0% to 9.0% and
amputation rates from 8.1% to 6.4%, although the latter
decrease was not statistically significant. One year mortality
remained unchanged (41.0% vs. 42.5%). The one year
amputation rate decreased over time from 14.8% to 11.0%.
Similar amputation rates, mortality, and time trends were
reported from Sweden.23,25,26 One investigation from the
National Inpatient Sample in the USA studied 162 240 pa-
tients with ALI from 2002 to 2013; 33 615 (20.7%) under-
went thrombolysis. The authors concluded there could be
an association between the increased use of thrombolysis
and other endovascular procedures and improved
outcome.27 There are few data on the level of major
amputation after ALI, but in one large cohort study 34% of
amputations done within 30 days were performed above
the knee.25
Better detection and medical treatment of AF and
atherosclerotic disease has probably contributed to this
decrease in the incidence of ALI.18 Primary preventionstrategies, including smoking cessation advice, have also
probably contributed.28
1.6. Benefit vs. harm
ALI is both a life and limb threatening disease. This makes
decisions about best care complex. Often the limb is not
salvageable owing to irreversible ischaemia, and amputa-
tion may be needed to save the patient’s life; sometimes
the patient is very frail and an attempt to save the limb will
pose a significant risk to the patient’s life. In 1994, in
Gloucestershire, UK, 24% of individuals with ALI did not
undergo a revascularisation attempt.22 However, these data
may not reflect contemporary practice, and it may be
questioned whether they are still valid. Decisions about
care need to be made in a compassionate and sympathetic
way but based on available clinical evidence, and after
discussion with patients and their relatives. Patients are
often elderly and their ability to comprehend the com-
plexities of their situation, while in pain and often on opiate
analgesia, is difficult. There may be issues such as the ability
to consent. Clinicians must ensure appropriate consent is
obtained before treatment. The following list of factors
should be taken into account before deciding on treatment.
1.6.1. Patient’s age, fitness, and comorbidities. Patients
suffering from underlying or associated diseases may need
specific considerations concerning the therapeutic approach.
ALI is usually a disease of the elderly, is associated with
general frailty, and may be an end of life problem.29 Rec-
ognising when a patient is dying is important, and not always
easy. This situation, when the thrombosis is part of ending
life, is sometimes referred to as agonal thrombosis. For
example, in a small series of patients who developed ALI
while in hospital with other medical conditions, none sur-
vived active treatment.22 The elderly may tolerate an em-
bolectomy but not do so well if a distal bypass is needed to
save the limb. The benefit of revascularisation in nonage-
narians with lower limb ischaemia is limited by high mor-
tality at one year.30 These patients often present with
concomitant emboli to other arterial beds, and they may die
from embolic stroke or embolic bowel ischaemia.
Recommendation 1
For patients with acute limb ischaemia it is recommended:
that the best interests of the patient are considered before
deciding on treatment; to obtain informed consent to
management if at all possible; and to record decisions clearly.
Class Level References
I C Consensus
Recommendation 2
For patients with acute limb ischaemia and underlying
malignant disease, active revascularisation in selected
patients should be considered, as the immediate post-
operative outcome is comparable to patients without
malignancy.
Class Level References
IIa B Mouhayar et al. (2014),32 Tsang
et al. (2011),33 Morris-Stiff and
Lewis (2010),31 Nicolajsen
et al. (2015)34
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derlying malignancy causing prothrombotic states, including
patients being actively treated, for example with chemo-
therapy. The malignancy is usually advanced, and treatment
often has dismal results. Limb salvage rates are poor and
most patients are not alive six months later, usually as a
result of their underlying cancer.31 Decisions about the
management of patients with malignancy should be indi-
vidualised with the help of oncologists, as active treatment
in selected patients can yield good results both from
treatment of the leg and the cancer.32,33 In a prospective
study from Denmark with 26 years of follow up, patients
with ALI and a newly diagnosed cancer had a higher risk of
amputation than similar patients without cancer (hazard
ratio [HR] 0.09 vs. 0.06), and patients with cancer also had a
higher mortality rate (HR 0.67 vs. 0.37).34
1.6.2. Current and projected quality of life. This is more
important than the patient’s general fitness. Elderly patients
may be living alone and independent but need to move to
residential accommodation if they become an amputee. A
threat to their independence could be an argument for taking
extra risks to try and obtain limb salvage. Similarly, under-
standing limb function is important. It may not be appropriate
to attempt to save the limb of a patient who is wheelchair
bound, while doing a brachial embolectomy to ensure good
hand and arm function may ensure continued independence.
1.6.3. What can be offered? Unless the limb is irreversibly
ischaemic, there is usually some treatment that can be
offered to most patients. Options may be surgical or endo-
vascular (thrombectomy or thrombolysis). Medical antith-
rombotic/anticoagulation (AC) treatment alone may be
sufficient, which should be considered especially in frail pa-
tients with limited or no ability to be mobilised. The
complexity of decision making is where a larger, potentially
more hazardous surgical procedure has a greater predicted
chance of success, but also a greater risk of complications,
including death. This is where experience is required in the
treating clinician, and good communication with patient and
relatives is vital.
1.6.4. The wishes of patients and their relatives. Many
elderly patients with severe ALI will not accept the possibility
of leg amputation initially, preferring that their life ends. The
situation requires a clear discussion with a vascular surgeon
who can explain all the available options, including that good
quality of life can be obtained, even as an amputee. Involve-
ment of relatives is paramount as optimal outcomes are
achieved if the patient, their relatives, and the surgeon can
agree on the proposed management. Occasionally, relatives
will adopt a more active approach to treatment and try to
persuade the patient to have a procedure that they do not
agree to.This is a difficult situation that needs careful handling
by an experienced and sympathetic clinician. It is fundamental
that the discussion and decisions are clearly recorded in the
case notes to avoid later legal challenge by relatives. Irre-
spective of the decision of whether to amputate or not, pa-
tients need psychological support.2. DIAGNOSIS
ALI is a medical emergency, and it is important that the
diagnosis is confirmed promptly, and proper treatment is
started in order to prevent limb loss and other severe com-
plications. Patientswith acute on chronic limb ischaemia often
have a history of intermittent claudication and have risk fac-
tors for PAD, such as smoking, hypertension, renal insuffi-
ciency, and diabetes. It is important to include patient history
in the clinical assessment. The clinical presentation of ALI
depends on the location and duration of the arterial occlusion,
the presence of collateral circulation, and the metabolic
changes related to tissue ischaemia. Typically, after occlusion
of a native artery, the signs of ischaemia are located one level /
joint distal to the level of occlusion (Fig. 3).
In a study of the Swedvasc registry comprising 16 229 pa-
tients who underwent revascularisation for native artery ALI
(thus excluding ALI secondary to re-occlusion of previous
vascular surgery), the cause for limb ischaemia was embolic in
44%, thrombotic in 53%, and a popliteal artery aneurysm (PA)
in 3%.23 The clinical differentiation between acute embolic
and thrombotic occlusion can sometimes be difficult. A sud-
den onset of ALI symptoms is typical for arterial embolism.
Patients with ALI due to thrombosis will present as a more
gradual aggravation of symptoms, becausemost patients with
pre-existing PAD compensate by increased collateral circula-
tion. Most embolic occlusions are caused by cardiac dysryth-
mias, and two thirds are associated with AF, while 20%
originate from ventricular thrombus (that may be of diverse
aetiology).35 In low and middle income countries valvular
heart disease remains an important cause of ALI.2.1. Clinical examination
The classic “six Ps” (pain, pallor, pulselessness, poikilothermia
[perishing with cold], paraesthesia, and paralysis) can help to
appreciate the clinical severity of ischaemia. However, in
180 Martin Björck et al.clinical practice all six signs are rarely encountered, unless
there is a severe ALI in a patient with otherwise normal ar-
teries. Detection of peripheral pulses is enhanced by deter-
mination of the ABI using hand held Doppler.36,37 ABI in ALI is
also a predictor of outcome and an index<0.7 is critical.38 The
loss of sensory and motor function are symptoms of a
threatened limb with a need for immediate revascularisation.
The Rutherford classification for ALI (Table 2) is the most
commonly used to determine whether the limb is viable,
threatened, or irreversibly ischaemic, and to guide clinical
management.2 It is important that both legs are examined to
exclude bilateral disease and to look for bilateral conditions
such as PA. Physical examination should also include all other
peripheral pulses and looking for signs of visceral ischaemia
(abdominal tenderness). Patients with neurological impair-
ment or deep venous thrombosis may have clinical signs and
symptoms similar to ALI. Given the cardiac origin of embolic
occlusions, a focused cardiac examination should be per-
formed, without interfering with or delaying the treatment of
ALI.
Many patients with ALI are not admitted primarily to
vascular specialists. However, after thorough clinical work
up (see above) by any competent doctor, the diagnosis of
ALI is usually made easily. Early diagnosis is important in
order to save time, and increase the chance of successful
treatment.Figure 3. Clinical aspect of acute ischaemia of the right lower
limb.2.2. Imaging modalities
The time needed to obtain any type of imaging should be
weighed against the urgency of revascularisation. If non-
invasive imaging is chosen, it is important that this does
not delay subsequent treatment.
Virtually all data on the diagnostic accuracy of non-
invasive imaging modalities come from studies in patients
with chronic limb ischaemia, the majority having intermit-
tent claudication. Little is known about the accuracy of
imaging of the lower limb arteries in the acute (non-
trauma) setting. Although the accuracy of the various im-
aging modalities in the setting of ALI is unknown, sensitivity
and specificity to detect arterial occlusions is unlikely to be
significantly different from that seen in chronic PAD. How-
ever, the possibility of imaging the outflow arteries is usu-
ally more difficult in patients with ALI, owing to the lack of
collaterals.
2.2.1. Digital subtraction angiography. In terms of diag-
nostic accuracy, digital subtraction angiography (DSA) is still
considered the standard investigation for ALI.39 DSA can
delineate aetiology and offers the advantage of allowing
treatment in the same setting; in modern practice this
should be considered in association with endovascular
surgery. The presence of a crescent shaped occlusion, or
meniscus sign, combined with the normal appearance of
the remaining vessels is typical of an embolic occlusion
(Fig. 4). Thrombotic occlusion is typified by other areas of
atherosclerosis and some existing collaterals. Arterial access
for the DSA should be chosen in such a way that both inflowand outflow can be evaluated. Intra-arterial vasodilators can
be used to reduce vasospasm in the vessels distal to the site
of occlusion, and thus enhance visualisation of the distal
arterial bed.40 In patients with severe renal insufficiency,
carbon dioxide angiography may be considered.41
2.2.2. Duplex ultrasound. Data on the diagnostic accuracy
of duplex ultrasound (DUS) in the setting of ALI are also
scarce. DUS has a sensitivity of 88% (95% confidence in-
terval [CI] 80% e 98%) and a specificity of 96% (95% CI 89%
e 99%) to detect a stenosis > 50% or occlusion in patients
with chronic PAD.42 DUS is able to obtain the necessary
information in 90% of cases where revascularisation is
considered, including patients with ALI, and is an accurate
modality with which to detect complete or incomplete
obstruction in the common femoral, superficial femoral,
and popliteal arteries, and in bypass grafts.43 The diag-
nostic accuracy is lower for detection of stenoses or oc-
clusions in the tibial arteries, but ALI is rarely caused by
such distal lesions. Therefore, DUS should not be used as a
single modality in order to rule out arterial occlusion. In
BA
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dilatation of the artery above the occlusion, in comparison
with the contralateral limb is suggestive of an embolic
occlusion, whereas a 0.5 mm diameter reduction correlates
well with a thrombotic occlusion.44 In a retrospective
analysis of 181 patients with ALI, 90 patients were treated
based on DUS as the sole pre-operative modality, with
similar outcomes to those who had pre-operative DSA and
computed tomography angiography (CTA).45 The clinical
applicability of DUS is limited in the acute setting, because
it is not always available 24/7.
2.2.3. Computed tomography angiography. CTA requires
administration of non-ionic contrast to obtain sufficient
opacification of the arteries of the legs without venous or
tissue enhancement. Although there is an association be-
tween the use of iodinated contrast and acute kidney injury,
this is a relative problem when facing a potentially life
threatening condition. Furthermore, the recent guidelines
from the European Society for Urogenital Radiology have
lowered the threshold for safe administration of contrast to
an estimated glomerular filtration rate of 30 mL/minute/
1.73 m2.46 In a large cohort of 1 017 patients treated for ALI
there was an association between contrast induced acute
kidney injury and increased all cause mortality, but there
were multiple potential confounders associated with
comorbidities.47
Anatomical coverage usually extends from just cranial to
the origins of the renal arteries down to the feet, with an
average scan length of around 120 cm. If the distal vessels
are not well opacified (e.g., in the case of femoropopliteal
aneurysm or slow flow in the setting of cardiac failure), a
secondary acquisition may be necessary.48 Current CT
technology allows coverage of the entire body in a single
acquisition, with short acquisition times, high resolution,A B
Figure 4. (A) Digital subtraction angiography image of acute on
chronic occlusion. Note the irregular proximal margins and col-
laterals typical of thrombotic occlusion. (B) Fluoroscopic image
demonstrating stasis of contrast on embolic occlusion. Note the
concave margin typical of embolic occlusion.and the possibility of post-processing axial images into re-
constructions that provide similar accuracy to DSA images
(Fig. 5).
Most modern hospitals can offer expedited CTA. An
advantage of CTA is that it allows evaluation of the thoracic
and abdominal aorta to seek a potential embolic source,
and also the mesenteric vessels to look for other emboli.
Extravascular findings may be seen that are related to the
aetiology of ALI (e.g., in some types of popliteal artery
entrapment) or are of clinical importance. In one study,
relevant findings needing further investigation or treatment
were seen in up to 74% of investigations.49 Four (2.8%)
patients in the latter series had previously unknown ma-
lignancy.49 CTA is considered more useful than DSA because
it can combine evaluation of the possible primary cause of
ALI with high resolution evaluation of the outflow tract and
provide a roadmap to guide treatment. In patients with
chronic PAD, CTA has a sensitivity of 96% (95% CI 93% e
98%) and a specificity of 95% (95% CI 92% e 97%) for the
detection of stenoses > 50% or occlusions from the aorta to
the popliteal arteries.50 In a systematic review including a
total of 891 trauma patients, the sensitivity and specificity
of CTA were both 100% to detect arterial injury in a single
investigation.51 In the only study in the setting of ALI the
sensitivity of CTA was 42/43 (98%) for the detection of an
occluded artery vs. DSA or surgery.52
2.2.4. Contrast enhanced magnetic resonance angiog-
raphy. In contrast enhanced magnetic resonance angiog-
raphy (CE-MRA), like conventional angiography, contrast
agent injection enables the generation of images that canFigure 5. Aneurysmal persistent sciatic artery with acute
thrombosis of the popliteal artery. Computed tomography angi-
ography: (A) three-dimensional reconstruction and (B) centre line
reconstruction.
182 Martin Björck et al.visualise both arteries and veins. Arteries are visualised if
image acquisition is performed during the arterial phase of
the bolus. The vascular enhancement is a transient and
dynamic process; hence, the critical element to be set for a
CE-MRA, as with CTA, is the proper timing for image
acquisition. CE-MRA is characterised by long examination
times, limited availability, and therefore not frequently used
in ALI. Image quality may be affected by artefacts related to
venous return (which might be overcome by four dimen-
sional imaging where contrast media inflow and outflow are
used to distinguish between artery and vein), as well as any
metallic implants (surgical clips and stents). In patients with
chronic PAD the diagnostic accuracy of CE-MRA is similar to
that of CTA, with a sensitivity and specificity for the
detection of a stenosis > 50% of 93% (95% CI 91% e 95%)
and 94% (95% CI 93% e 96%), respectively.50 To date, no
studies have evaluated CE-MRA in the setting of ALI.
2.2.5. Summary of imaging modalities. Based on current
evidence, DSA, CTA, DUS, and CE-MRA can all be considered
for imaging in patients with ALI, and may be used based on
local expertise, availability around the clock, and preference
(Table 3). CTA is used most often because of its availability,
and should be performed for treatment planning, unless the
ischaemia is too severe to allow time for additional imaging.
The role of CE-MRA seems limited, mainly because of
limited availability out of office hours, and because it has
not been evaluated in patients with ALI.Recommendation 3
For patients presenting with a possible diagnosis of acute
limb ischaemia, it is recommended that clinical assessment
is performed urgently by a vascular specialist, who should
be responsible for planning further investigation and
management.
Class Level References
I C Consensus
Recommendation 4
For patients presenting with acute limb ischaemia, the
Rutherford classification for acute limb ischaemia is
recommended for clinical evaluation.
Class Level References
I C Rutherford et al. (1997)22.3. Laboratory markers of ischaemia
The pre- and peri-operative measurement of biomarkers in
ALI could potentially serve to assess the level of ischaemia
and predict which patients will not tolerate efforts at limb
salvage, or who will have poor functional outcomes after
salvage. Few studies in humans have validated the clinical
usefulness of markers of ALI and reperfusion.53 Myoglobin
and creatine kinase (CK) are well known markers of skel-
etal muscle damage, due to ischaemia and rhabdomyol-
ysis, and may help in determining the level of subsequent
resuscitative support that is required. Myoglobin is known
to precipitate in the renal tubules and cause loss of renal
function in patients with rhabdomyolysis, but has not been
studied as a prognostic factor in patients with ALI. CK is
used widely as marker of ischaemia reperfusion injury (IRI)
and might assist the peri-operative management of ALI byTable 3. Summary of imaging modalities in acute limb ischaemia
Modality Availability* Accuracy
Duplex ultrasound  þþ
Computed tomography angiography þþ þþþ
Contrast enhanced magnetic resonance
angiography
þ þþ
Digital subtraction angiography þþ þþþ
* Availability is very much dependent on local conditions.estimating the risk of major amputation or limb preser-
vation. Indeed in a series of 97 patients with mild and
severe symptoms of ALI, the risk of amputation in patients
with normal CK at presentation was 4.6% vs. 56.3% in
those with elevated CK.54
In a series of 46 patients with ALI undergoing embolec-
tomy, cardiac troponin I was > 0.2 ng/mL in 24 but did not
have prognostic value with regard to in hospital mortality.55
A correlation with limb salvage was not studied. C reactive
protein (CRP) and alpha-1-acid glycoprotein levels were
studied in 75 patients with acute arterial occlusion. Post-
operative complications were detected with a sensitivity
and specificity of 84% and 95%, respectively, using a CRP
level of 49 mg/L as the cut off.56 In a retrospective analysis
of 254 patients who underwent embolectomy for ALI, a
neutrophil / lymphocyte ratio > 5.2 had a sensitivity of 83%
and a specificity of 63% to detect the need for amputation
within 30 days.57 There are no data in the literature
correlating levels of lactate with severity of ALI. The 2017
ESVS Mesenteric Guidelines recommended against using
serum lactate to diagnose acute mesenteric ischaemia, as it
is a late sign of generalised hypoperfusion, and is often
normal in the early acute phase.58
Summarising the scarce evidence on the use of bio-
markers as prognostic factors in patients with ALI shows
that there are no studies that support the routine use of
biomarkers to predict limb salvage and survival after ALI.Invasiveness Therapeutic
potential
Evaluation of entire vascular
tree and adjacent structures
e e þ
e e þþþ
e e þþ
þ þ þ
Recommendation 7
For patients presenting with acute limb ischaemia, duplex
ultrasound or contrast-enhanced magnetic resonance
angiography may be considered for alternative imaging
before starting treatment, depending on availability and
clinical assessment.
Class Level References
IIb B Jens et al. (2013),50,51 Collins
et al. (2007),42 Hingorani et
al. (2008),43 Crawford et al.
(2016)45
Recommendation 8
For patients presenting with acute limb ischaemia, it is not
recommended to use results of myoglobin and creatine
kinase on admission to base the decision to offer
revascularisation or primary amputation.
Class Level References
III C Watson et al. (2014),53 Currie et
al. (2007)54
Recommendation 5
For patients presenting with acute limb ischaemia, diagnostic
imaging is recommended to guide treatment, provided it does
not delay treatment, or if the need for primary amputation is
obvious.
Class Level References
I C Weiss et al. (2017)39
Recommendation 6
For patients presenting with acute limb ischaemia, computed
tomography angiography is recommended as the first line
modality for anatomical imaging.
Class Level References
I B Jens et al. (2013),50,51 Jakubiak
et al. (2009)52
Recommendation 9
For patients with acute limb ischaemia awaiting
revascularisation, heparin is recommended.
Class Level References
I C Aboyans et al. (2018),4 Gerhard-
Herman et al. (2017),59 Alonso-
Coello et al. (2012)60
Recommendation 10
For patients with acute limb ischaemia awaiting
revascularisation, supplemental oxygen is recommended.
Class Level References
I C Berridge et al. (1989)64
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3.1. Initial management
Initial medical treatment of ALI includes appropriate analgesia
and intravenous administration of unfractionated heparin
(UFH): initially 5 000 IU, or 70e100 IU/kg, followedby infusion,
dose adjusted to patient response, andmonitored by activated
clotting time or activated partial thromboplastin time (APTT).
The aim is to reduce further embolism or clot propagation, and
to provide an anti-inflammatory effect.4,59 Although this
approach is widely accepted, no recent randomised study has
been done to confirm the benefit of UFH for ALI, nor has any
randomised study compared unfractionated UFH with other
anticoagulants.60 In an RCT performed in the 1980s, patients
undergoing open surgery for emboli either had 5 000 IU UFH
pre-operatively, followed by full intravenous heparinisationplus warfarin until they were effectively anticoagulated, or no
anticoagulant treatment.61 This study showed no obvious
benefit of this level of AC, but an expected increase in bleeding
complications was seen. However, the study design made it
impossible to draw any conclusion regarding the benefit and
safety of only giving a single dose of pre-operativeUFH. A study
of 87 patients in the USA who needed transfer to a vascular
centre (36%with class IIb ischaemia), showed that although 76
received UFH before transfer, only 44 (58%) reached thera-
peutic levels, and those not achieving therapeutic levels had a
higher re-intervention rate (47%).62
In patients with confirmed or suspected heparin induced
thrombocytopenia, non-heparin anticoagulants such as
lepirudin, argatroban, or danaparoid are options.63 Advice
from a haematologist may be valuable. Other measures that
may be beneficial in patients with ALI include intravenous
hydration and supplementary oxygen,64 and lowering the
foot end of the bed (anti-Trendelenburg position).
3.2. Adjuvant prostanoid treatment
Studies evaluating the role of other adjuvant pharmaco-
logical treatments for ALI have mainly focused on prosta-
glandin analogues. One study randomised 300 patients to
either surgical treatment with peri-operative iloprost (intra-
operative intra-arterial bolus plus post-operative intrave-
nous infusion for 4 e 7 days) or placebo.65 The study did
not demonstrate a significant difference in the combined
incidence of death and amputation (primary end point), but
iloprost used as an adjuvant to surgery significantly reduced
peri-operative mortality from 10.6% to 4.7%, as well as the
overall rate of cardiovascular major events. A post-hoc
analysis showed that the combined incidence of death
and amputation was significantly reduced in a subgroup of
elderly patients (aged > 70 years) treated with iloprost.66 A
more recent study randomised 204 patients to peri-
operative administration of liposomal prostglandin E1 or
placebo.67 The incidence of peri-operative mortality/major
adverse limb events (MALE) was significantly reduced in
patients receiving liposomal prostaglandin E1 (13.2% e
5.1%). Although these studies report benefit from adjuvant
prostanoid therapy, it has not found widespread favour.
Recommendation 11
For patients with acute limb ischaemia awaiting
revascularisation, adequate analgesia and intravenous
rehydration are recommended.
Class Level References
I C Aboyans et al. (2018),4 Gerhard-
Herman et al. (2017),59 Alonso-
Coello et al. (2012)60
Recommendation 12
For patients with acute limb ischaemia, treated by open
surgery, prostacyclin analogues may be considered during
and after revascularisation.
Class Level References
IIb B De Donato et al. (2006),65,66 Li et
al. (2013)67
Recommendation 14
It is recommended that patients with acute limb ischaemia
should have access to treatment in a hybrid theatre, or
operating theatre with C arm equipment, and by a clinical
team able to offer a full range of open or endovascular
interventions during a single procedure.
Class Level References
I C Consensus
Recommendation 13
It is recommended that patients diagnosed with acute limb
ischaemia in a non-vascular centre be transferred to a
vascular centre that offers the full range of open and
endovascular interventions with an urgency that depends
on the severity of the ischaemia.
Class Level References
I B Grip et al. (2018),23
Bath et al. (2019)27
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Patients with ALI should be treated by specialists in vascular
and endovascular therapies, in centres with a full range of
facilities to manage patients with vascular diseases. This
may mean that a patient will need to be transferred from a
non-vascular centre for treatment, if appropriate.23 The
urgency of transfer will depend on the severity of the
ischaemia, with patients with motor or sensory loss (Ruth-
erford IIb) requiring urgent transfer.
The urgency of treatment will depend on the severity of the
limb ischaemia, graded using the Rutherford clinical classifi-
cation (Table 2).2 If there is a neurological deficit in the limb,
particularly involving motor loss (Rutherford IIb), urgent
revascularisation is mandatory. Various revascularisation
techniques can be used, including surgical thrombo-
embolectomy, bypass, percutaneous catheter directed
thrombolysis (CDT), thrombus aspiration / mechanical
thrombectomy (with or without thrombolysis) and hybrid
procedures including thrombendarterectomy. The strategy
employed will depend on a number of factors, including the
expertise and facilities of the treating team, andpatient factors
such as the duration and severity of ALI, the location and cause
of the occlusion, comorbidities, and therapy related risks.
Other ESVS Guidelines, such as the recently published 2019
Clinical Practice Guidelines on the Management of Abdominal
Aorto-iliac Artery Aneurysms,7 defined minimum volumes for
centres treating a certain disease. Data suggest that being able
to offer both open and endovascular surgery 24/7 may be
associated with improved outcomes, as patients treated by an
endovascular first strategy have improved survival.23,27 Being
able to offer both treatment modalities 24/7 requires a certain
treatment volume,which is self evident, even if robust data are
lacking to substantiate this assumption.There is a difficult trade
off between the cost of delay, when a patient is transferred,
and the limited expertise that may be available in the local
hospital where the patient presents. All these patients can be
discussed with a vascular surgeon on call; however, the dis-
cussion should take place before the difficult decision is made
whether to refer the patient to another centre or treat on sitewith potentially limited resources. Smaller hospitals, particu-
larly if they are situated in remote areas, should be integrated
into a network facilitating rapid referral, whenever indicated.3.4. Open revascularisation techniques
3.4.1. Thrombo-embolectomy. Since its introduction in
1962 by Fogarty, balloon thrombo-embolectomy has
remained the standard treatment of ALI caused by embolic
occlusion,68 particularly when dealing with occlusion of an
otherwise normal artery. However, this is an increasing
rarity in modern surgical practice, as most patients with AF
have co-existing vascular disease. A single femoral incision is
usually adequate to perform thrombo-embolectomy of
unilateral iliac, femoral or profunda clots. When the occlu-
sion extends up to the aortic bifurcation, it is important to
avoid clot dislodgement over the bifurcation into the other
leg. Balloon protection of the contralateral common iliac
artery under fluoroscopic guidance, or manual compression
of the contralateral common femoral artery, are sometimes
used to reduce the risk of contralateral embolisation. For
more details on acute aortic occlusion (AAO), see section 6,
Acute Aortic Occlusion With Bilateral Lower Limb Ischaemia.
If the occlusion is in the popliteal artery or below, com-
plete removal of occluding thrombus may be difficult from
the groin, and direct exploration of the below knee popli-
teal artery should be considered. This enables passage of
the embolectomy catheter into all three tibial arteries
separately to clear any obstructing clot. A transverse arte-
riotomy is preferred in the below knee popliteal artery to
prevent narrowing when the incision is repaired. Patch
angioplasty is recommended for surgeons who prefer lon-
gitudinal arteriotomy. In patients with distal embolic oc-
clusions, a few retrospective studies with limited numbers
describe microtibial embolectomy via pedal arteries.69,70
Femoral embolectomycanbedoneunder local anaesthethia,
but an anaesthetist should always be present in theatre, even if
the procedure is under local anaesthesia, to administer anal-
gesia and sedation, and to treat any dysrhythmia or cardiac
Recommendation 17
For patients requiring an infrainguinal bypass procedure for
acute limb ischaemia, the preferential use of a vein graft
should be considered.
Class Level References
IIa C Marques de Marino et al.
(2016),77 Grego et al. (2004)78
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 185complication on reperfusion.31 Popliteal artery exploration
usually requires general or regional anaesthesia.
Technical improvements to surgical embolectomy have
been introduced with wire guided ballons for a precise
approach to specific vessels and to avoid iatrogenic injury
(i.e., dissection), ante- and retrograde approach, and fluo-
roscopic guidance.71 These approaches are associated with
improved vessel clearance.71e73
A number of reports describe contemporary outcomes of
surgical embolectomy as the primary treatment of ALI due
to arterial embolism. In one report of 170 patients, 82
(49%) had AF.74 In most cases, a femoral approach was used
(aortic, iliac, and infra-inguinal emboli), although 10 (6%)
required bypass surgery. Additional local thrombolysis was
performed in 16% of patients and fasciotomy was needed in
39%. The 30 day mortality rate was 18% and a further 15%
had a major amputation within 90 days. The five year
freedom from amputation and survival estimates were 80%
and 41%, respectively. This study typifies the ongoing high
morbidity and mortality of embolic ALI.Recommendation 18
For patients undergoing open and endovascular surgery
for acute limb ischaemia, completion angiography is
recommended.
Class Level References
I C Lipsitz and Veith (2001),73
Zaraca et al. (2010)79
Recommendation 19
For patients with residual thrombus after open surgery for
acute limb ischaemia, intra-operative local thrombolysis
may be considered.
Class Level References
IIb C Gonzalez-Fajardo et al.
(1995),84 Witz et al. (2002),82
Comerota and Sidhu (2009),85
Knaus et al. (1993),80 Beard et
al. (1993),81 Garcia et al.
(1990)83
Recommendation 15
For patients requiring surgical thrombo-embolectomy for
acute limb ischaemia, regional or local anaesthesia may be
considered, but always with an anaesthetist present.
Class Level References
IIb C Morris-Stiff et al. (2009)75
Recommendation 16
For patients requiring surgical thrombo-embolectomy for
acute limb ischaemia, the use of over the wire embolectomy
catheters under fluoroscopic control should be considered.
Class Level References
IIa C Pemberton et al. (1999),71 de
Donato et al. (2014),72 Lipsitz
and Veith (2001)733.4.2. Surgical bypass. Surgical bypass may be the primary
treatment for ALI, or be used if intravascular recanalisation
cannot be achieved. Bypass is more often indicated for acute
onchronic ischaemia.The techniques usedare generally similar
to those for chronic limb threatening ischaemia. The Vascular
Study Group of New England reviewed 5 712 infra-inguinal
bypasses done between 2003 and 2011, 323 (5.7%) of which
were done for ALI.76 More patients with ALI had previous
endovascular interventions (41.1% vs. 28.8%) and / or ipsilat-
eral bypasses (32.8% vs. 23.5%) than those operated on for
chronic limb ischaemia. More prosthetic bypasses were used
(40.6% vs. 32.6%) and there were more complications after
surgery in the ALI group (rate of severe events was 19.8% vs.
11.6% in the chronic limb ischaemia group). Overall results at
one year were also worse after bypass for ALI (major ampu-
tation rate 22.4% vs. 9.7%; death 20.9% vs. 13.1%; and
amputation free survival 62.8% vs. 77.4%).
There are no RCTs comparing vein with prosthetic grafts
in the acute setting, but two retrospective studies reportedbetter patency rates with vein grafts.77,78 Preferential use of
a prosthetic graft may be considered in a patient with se-
vere ischaemia (Rutherford grade IIB), where urgent
revascularisation is necessary.3.4.3. Completion imaging after surgery or embolectomy.
There is consensus to recommend completion angiography
after thrombo-embolectomy to document the outcome, as
residual thrombus is common and its identification is
associated with a reduced risk of re-intervention and limb
loss.73,79 If residual thrombus is found after embolectomy,
further embolectomy or bypass may be considered. A
widely used alternative is intra-operative instillation of
thrombolytic agents (e.g., recombinant tissue plasminogen
activator [rtPA] 4 e 10 mg) directly into the artery down-
stream with the aim of dissolving residual thrombus.80e82
No controlled studies exist, and the benefit to limb
salvage remains unclear, but severe bleeding complications
are rare.83e85 There are wide variations in techniques and
doses of thrombolytic agents employed, which makes firm
conclusions difficult. Although completion imaging is rec-
ommended, and is straightforward in most modern oper-
ating rooms, there are situations when an exception to the
rule can be made, such as in a patient with renal insuffi-
ciency and clearly palpable foot pulses.
Recommendation 20
For patients with acute limb ischaemia caused by graft
occlusion, identification and treatment of the cause of graft
occlusion is recommended.
Class Level References
I C Shoenfeld et al. (1987),86 Cohen
et al. (1986),87 Whittemore et
al. (1981),88 Bandyk et al.
(1990),89 Edwards et al.
(1990),92 Sanchez et al. (1996)93
186 Martin Björck et al.3.4.4. Treatment of acutely occluded bypass grafts. Some
patients with acute bypass graft occlusion do not develop
critical ischaemia, and in this situation the no treatment
option may be safest. In those who are symptomatic,
treatment will depend on the situation and material used
for the primary bypass. If the occluded graft is vein, both
proximal and distal anastomoses usually require surgical
exploration. In such cases, over the wire embolectomy
catheters can be useful to deal with valve cusps. Identifi-
cation (and treatment) of the underlying cause of throm-
bosis is crucial.
Thrombo-embolectomy alone is unlikely to restore the
circulation in an occluded vein graft.86,87 If no anatomical
explanation for graft failure can be identified, the prognosis
for long term patency and limb salvage is poor. If the cause
of the graft failure (e.g., anastomotic stenosis or poor
runoff) is identified and addressed, more favourable out-
comes have been reported.88,89 ALI due to early graft oc-
clusion (within 30 days of insertion) is often a technical
issue (poor vein quality, inadequate inflow or outflow,
anastomotic stenosis, graft torsion, valve defects, or clamp
related damage). ALI caused by late graft thrombosis (> 30
days) is usually the result of progression of atherosclerosis
proximal or distal to the graft, atherosclerosis within the
graft, fibrotic stenosis or intimal hyperplasia in the graft, or
aneurysmal dilatation.86,87 No comparative studies have
specifically addressed the optimal treatment for occluded
bypasses causing ALI.
CDT is also an effective treatment for acutely occluded
bypasses. In a systematic review angiographic patency after
CDT was 82% for prosthetic and 61% for venous bypass
grafts.14 In a study from Sweden, 123 patients (67% with a
prosthetic graft) were treated between 2000 and 2008.90
The mean duration of thrombolysis was 19 hours. Only
29% of patients did not require additional intervention after
thrombolysis; 21% received open surgery, 39% had endo-
vascular treatment, and 11% a combination of both.
Amputation free survival was 89% at one month and 75% at
one year. Two haemorrhagic strokes occurred as immediate
complications (1.6%), and one was lethal. Major haemor-
rhage occurred in 13.2%. Mortality was 6.5% after one
month and 13% after one year. One advantage of throm-
bolysis is that it can uncover the reasons for bypass failure,
which can help plan secondary intervention to prolongTable 4. Overview of randomised controlled trials comparing
intravenous recombinant tissue plasminogen activator
Reference Patients
n
Thrombolytic regimens Amputation
survival at
n (%)
Berridge et al.
(1991)97
40 Intra-arterial low dose
infusion vs. IV infusion at
rates of 1, 2, 5, or 10 mg/h
16/20 (80)
14/20 (70)
Saroukhani et al.
(2015)98
38 Intra-arterial bolus +
infusions vs. IV
infusion over 2 h
16/20 (80)
12/18 (67)
Data are n (%). IV ¼ intravenous.patency (e.g., angioplasty of an anastomotic stenosis).
Thrombolysis may also increase the number of outflow
vessels available for subsequent bypass.913.4.5. Hybrid treatment. Although simple thrombo-
embolectomy or bypass still play a major role in the open
treatment of ALI, there is a trend for these patients to have
complex, multilevel occlusive disease; they may best be
treated by a combination of open and endovascular tech-
niques.72,94,95 After incomplete thrombo-embolectomy,
endovascular techniques such as intra-arterial thrombolysis
or thrombus aspiration / mechanical thrombectomy can be
used to remove any remaining clot. When completion
angiography reveals an underlying chronic stenosis, balloon
angioplasty or stenting can be performed to treat the un-
derlying lesion, and prolong patency. Similarly, endovascular
treatment may need to be supplemented by open surgery,
such as thrombendarterectomy or fasciotomy. For this
reason, optimal ALI treatment should take place in a hybrid
theatre, or operating theatre with a C arm, and by a clinical
team able to offer a full range of open or endovascular in-
terventions during a single procedure. Having said that,
there are situations when the patient’s condition and / or
the local hospital resources makes it necessary to perform
the procedure in a conventional operating room or an angio
suite in the radiology department.
Although hybrid procedures have gained widespread
acceptance, there are few data evaluating their potential
benefit for ALI. A recent multicentre retrospective study ana-
lysed the short term outcomes of 1 480 patients following
open surgical, endovascular, or hybrid treatment for ALI.96
Endovascular treatment was associated with a reduction in
the amputation rate vs. open and hybrid procedures. However,intra-arterial recombinant tissue plasminogen activator vs.
free
30 d
Major bleeding
n (%)
Stroke
n (%)
Distal embolisation
n (%)
vs. 0/20 (0) vs.
4/20 (20)
0/20 (0) vs.
1/20 (5)
1/20 (5) vs.
0/20 (0)
vs. 0/20 (0) vs.
0/18 (0)
0/20 (0) vs.
0/18 (0)
Not applicable
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intervention, or mortality. Another study evaluated 380 pa-
tients with ALI of the leg and found that those who had intra-
operative angiography after embolectomy had a higher rate of
intra-operative re-intervention, a higher rate of additional in-
terventions due to residual stenosis / occlusion and a lower
rate of re-occlusion after 24 months.79Recommendation 21
After open revascularisation for acute limb ischaemia,
simultaneous endovascular treatment addressing inflow or
outflow stenosis should be considered.
Class Level References
IIa C de Donato et al. (2014),72 Balaz
et al. (2013),94 Argyriou et al.
(2014),95 Davis et al. (2018)963.5. Thrombolysis
3.5.1. Systemic thrombolysis. Two small RCTs compared
intra-arterial with intravenous rtPA for ALI (Table 4).97,98
Intra-arterial rtPA was more effective than intravenous
rtPA in producing complete recovery at 30 days (n ¼ 16/20
vs. n ¼ 9/20; p ¼ .048),97,99 whereas amputation free
survival at 30 days appeared similar.97,98 In one study, there
were more bleeding complications after intravenous rtPA
(n ¼ 13/20; p < .001) and intra-arterial streptokinase (n ¼
6/20; p ¼ .02) than after intra-arterial rtPA.97 Complication
rates were also similar. Intravenous thrombolysis is no
longer in general use for ALI.A B
Figure 6. (A) Digital subtraction angiography showing a
Results after thrombolysis: (B) first control angiogram and
Recommendation 22
For patients with acute limb ischaemia, intravenous
thrombolysis is not recommended.
Class Level References
III A Berridge et al. (1991),97
Saroukhani et al. (2015),98
Robertson et al. (2013)993.5.2. Assessment before catheter directed thrombolysis.
Intra-arterial CDT can be performed in ALI with equivalent
results to surgery (Fig. 6).91,100,101 Initially, thrombolysis was
recommended only for patients with ALI and a limb that was
not immediately threatened, and not for thosewith severe or
progressive symptoms. However, a systematic review
showed that thrombolysis may also be used in patients with
more severe ischaemia (Rutherford class IIb),14 and that
outcomes were no worse for patients with motor deficit.
Retrospective studies showed similar results.102e104 In three
studies clinical success and amputation free survival were
inferior in patients with Rutherford class IIb than IIa
ischaemia, although this was the case for both CDT and
surgery.23,105,106 In patients with more severe ischaemia the
administration of thrombolysis may need to be enhanced by
increasing the dosage and / or combining it with other
endovascular techniques, described in this section.
Patients with acute onset claudication (Rutherford class I)
experience significant morbidity and mortality when treated
by thrombolysis for a condition that does not threaten their
limb.107 Moreover, many of these patients do not have
relief of symptoms in the longer term.108 Therefore, pa-
tients presenting with acute onset claudication should be
treated conservatively by best medical treatment and su-
pervised walking therapy.107 There is a need for future
research in this field (as discussed in section 9.3).
In contemporary series of patients with ALI treated by
thrombolysis, technical success rates are high (80% e
90%).17,25 Thrombolysis can be used for native artery oc-
clusions, graft and stent / stent graft thrombosis, and for
embolic occlusions and PA thrombo-embolism.23,26 Major
amputation free survival was reported to be 84% at 30
days,25 and around 75% at one year.37,104 Significant hae-
morrhage is the major risk (13% e 30%), and may require
the cessation of treatment. There is a small risk of intra-
cerebral haemorrhage (around 0.4% e 2.3%), which is
usually fatal.25,109
Thrombolysis is contraindicated in patients at increased
risk of bleeding, as haemorrhage is the most common
complication. The Working Party on Thrombolysis in theC
n occlusion of the pedal and posterior tibial arteries.
(C) second control angiogram.
Table 5. Contraindications to thrombolytic treatment for
acute limb ischaemia110
Absolute
1. Established cerebrovascular event (including transient
ischaemic attack) within the last two months.
2. Active bleeding diathesis.
3. Recent gastrointestinal bleeding (<10 d).
4. Neurosurgery (intracranial, spinal) within the last three
months.
188 Martin Björck et al.Management of Limb Ischaemia divided contraindications
into absolute and relative, major and minor (Table 5).110
Cancer was a contraindication in previous guidelines, but
this has been removed, opening up potential treatment of
this difficult and vulnerable group. Similarly, older age is
often considered to be associated with an increased risk of
intracranial haemorrhage, but there are confounders
explaining this association and therefore older age in itself
is not considered a relative contraindication.Recommendation 24
For patients with Rutherford grade IIa acute limb ischaemia,
it is recommended that (percutaneous) catheter-directed
thrombolysis is considered as an alternative to surgery.
Class Level References
I A The STILE trial (1994),91
Comerota et al. (1996),100
Enezate et al. (2017),11 Ouriel
and Veith (1998),101 Bath et al.
(2019)27
Recommendation 25
For patients with Rutherford grade IIb acute limb ischaemia,
(percutaneous) catheter-directed thrombolysis may be
considered if initiated promptly, and may be combined
with percutaneous aspiration or thrombectomy.
Class Level References
IIb B Ebben et al. (2019),14 Acosta
and Kuoppala (2015),17
Braithwaite et al. (1997),109
Grip et al. (2014),23 (2018)25
Recommendation 26
For patients with acute limb ischaemia undergoing
endovascular therapy, ultrasound guidance for arterial
access is recommended.
Class Level References
I A Marquis-Gravel et al. (2018)111
5. Intracranial trauma within the last three months.
Relatively major
1. Cardiopulmonary resuscitation within the last 10 days.
2. Major non-vascular surgery or trauma within the last 10 days.
3. Uncontrolled hypertension: >180 mmHg systolic or
>110 mmHg diastolic.
4. Puncture of non-compressible vessel.
5. Intracranial tumour.
6. Recent eye surgery.
Relatively minor
1. Hepatic failure, particularly those with coagulopathy.
2. Bacterial endocarditis.
3. Pregnancy.
4. Diabetic haemorrhagic retinopathy.
Recommendation 23
For patients with acute onset claudication (Rutherford grade
I) that does not threaten the limb, (percutaneous) catheter-
directed thrombolysis is not recommended.
Class Level References
III B Braithwaite et al. (1999),107
Korn et al. (2001)1083.5.3. Access for percutaneous thrombolysis. Complica-
tions as a result of vascular access for thrombolytic therapy
are the commonest cause of difficulty during the procedure.
Groin haematoma is common following percutaneous
puncture of the femoral artery. Through and through
puncture of the femoral artery for access (including punc-
ture of the posterior wall) should be avoided. Anterior wall
puncture alone is recommended, ideally assisted by ultra-
sound guidance. Ultrasound guided retrograde puncture
was superior to an anatomical landmark approach in pooled
results from five RCTs of coronary angiography.111 Ultra-
sound guidance leads to fewer attempts (odds ratio [OR]
0.24), reduced risk of venous puncture (OR 0.18), and most
importantly, fewer bleeding complications (OR 0.41).
There are no comparative studies on antegrade vs.
retrograde access to the femoral artery for thrombolysis.Antegrade access, particularly for distal infrainguinal
thrombolysis may facilitate torque and manoeuvrability to
traverse an occlusion. Antegrade access from the arm also
enables passage of an acutely angled aortic bifurcation, but
with modern techniques this is rarely an issue. Retrograde
contralateral access offers a stable position of a long
crossover sheath, reducing the risk of dislodgement and
bleeding.112 It also avoids the need for compression of the
inflow artery of the ischaemic leg once the catheter is
removed.3.5.4. Fibrinolytic drugs. Urokinase and rtPA are the most
widely used thrombolytic drugs for CDT. Multiple studies
have shown that the efficacy and safety of these medica-
tions are similar.99 The feasibility of newer agents such as
reteplase and tenecteplase have been described in retro-
spective cohort studies of CDT, but have never been
compared with urokinase or rtPA.113e120 However, rete-
plase plus intravenous abciximab was not superior to uro-
kinase plus intravenous abciximab in terms of reduced
amputation rates in a RCT.121
The guidelines of the Society of Interventional Radi-
ology122 recommend the use of weight related doses of
rtPA (alteplase) for CDT (0.02 e 0.1 mg/kg/hour). Most
clinicians use standard non-weight related doses, usually
between 0.25 and 1.0 mg per hour for low dose infusions.
Recommendation 28
For patients undergoing thrombolytic therapy for acute limb
ischaemia, routine monitoring of plasma fibrinogen is not
recommended.
Class Level References
III B The STILE trial (1994),91 Ouriel
et al. (1999),124 Arepally et al.
(2002),125 Hull et al. (2006),118
Marder et al. (2012),126
Poorthuis et al. (2017)127
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catheter based intra-arterial thrombolysis is 40 mg.122
In a recent systematic review a wide variety of treatment
protocols was found, and meta-analysis on dosages and
outcomes was not possible owing to heterogeneity.14 There
are a number of accelerated methods of CDT using higher
doses of thrombolytic drugs. Pooled results from 9 877
patients were not suitable for direct comparison, but
accelerated thrombolysis reduced treatment duration: 21.9
hours (95% CI 21.4 e 22.5) for high dose protocols (
75 000 IU/hour urokinase,  0.8 mg/hour rtPA, or  1.0 IU/
hour rtPA) vs. 32.7 hours with low dose protocols (< 75 000
IU/h urokinase or < 0.8 mg/hour rtPA or < 1.0 IU/hour
rtPA). Bleeding complications occured in 17.1% (95% CI 16.7
e 17.5) in high dose regimens and in 13.4% (95% CI 12.8 e
14.0) in low dose regimens. Clinical success appeared to be
comparable.
Two small RCTs compared accelerated with standard
thrombolysis. The first randomised 63 patients with symp-
tomatic peripheral arterial or bypass graft occlusions to high
dose (250 000 IU/hour for four hours and then 125 000 IU/
hour) or low dose (50 000 IU/hour) urokinase. They found
both regimens to be equally effective in achieving throm-
bolysis. The high dose group had significantly more (mostly
minor) bleeding complications (20% vs. 2.7%).123 A second
study investigated high dose rtPA (three doses of 5 mg
over 30 minutes, then 3.5 mg/hour for up to four hours,
then 0.5 e 1.0 mg/hour) vs. low dose rtPA (0.5 e 1.0 mg/
hour) in 100 patients.109 The median duration of throm-
bolysis was significantly shorter for the high dose group (4.0
hours vs. 20 hours). Clinical outcome and complications
were equivalent.Recommendation 27
For patients with acute limb ischaemia undergoing
thrombolysis, it is recommended that recombinant tissue
plasminogen activator or urokinase is used.
Class Level References
I A Robertson et al. (2013)99
Recommendation 29
For patients undergoing thrombolysis for acute limb
ischaemia, continuous systemic therapeutic heparinisation
is not recommended.
Class Level References
III B Berridge (1990),128 Ouriel and
Veith (1998),101 Grip et al.
(2014)253.5.5. Monitoring fibrinogen levels during thrombolysis.
Fibrinogen is depleted during thrombolysis, and its mea-
surement could be used to predict bleeding complications
or guide the dose of thrombolytic agent.117 While the
Surgery vs. Thrombolysis for Ischaemia of the Lower Ex-
tremity (STILE) trial reported a correlation between low
fibrinogen and haemorrhagic complications,91 the Pro-
urokinase vs. Urokinase for Recanalisation of Peripheral
Occlusions, Safety and Efficacy (PURPOSE) trial found a
negative correlation for low fibrinogen and major bleeding
but a relative risk of 1.39 for plasma fibrinogen < 1.0 g/L
and any bleeding.124 Three other studies found no associ-
ation between a drop in or low level of plasma fibrinogen
and haemorrhagic complications.118,125,126
Although there is some evidence that very low levels of
plasma fibrinogen (< 1.0 or < 1.5 g/L) are indicators of
bleeding risk, a systematic review concluded the predictivevalue of plasma fibrinogen for bleeding during thrombolysis
is unproven, so regular monitoring is not recommended.1273.5.6. Heparinisation during catheter directed thrombol-
ysis. Some authors recommend continuing UFH treatment
during thrombolysis. However, in the Thrombolysis or Pe-
ripheral Arterial Surgery (TOPAS) trial, the concurrent use of
UFH intravenously with a target activated partial thrombo-
plastin time 1.5 e 2 times baseline was associated with an
increased risk of major bleeding (RR 2.19, 95% CI 1.13 e
4.24). One small RCT investigated the effect of 250 IU/hour of
intra-arterial UFH,97 but no benefit (or disadvantage) was
observed. Another observational study compared two hos-
pitals with different strategies.25 All patients received
thrombolysis using rtPA and an UFH bolus at the start of the
procedure. Bleeding complications were less common in the
centre without a continuous UFH infusion (21.4% vs. 36.7%),
but in multivariable analysis the UFH infusion was not an
independent risk factor for bleeding. Treatment success was
similar in the two centres. Some authors use a low dose UFH
infusion through the catheter sheath to maintain its patency
and prevent pericatheter thrombosis, but no controlled
studies exist. Likewise, there is no evidence of any benefit
from low molecular weight heparin (LMWH) during CDT.3.5.7. Complications after thrombolysis. Patients receiving
thrombolysis for ALI are at risk of a number of limb and life
threatening complications. They should be managed in a
facility by nursing and medical staff familiar with vascular
patients and the complications of thrombolysis, but not
necessarily intensive care.129 During the thrombolytic infu-
sion they should undergo regular monitoring to assess both
vital signs and, in particular the condition of the treated
limb. Specific complications of thrombolysis include
bleeding, distal embolisation, progressive ischaemia, and
compartment syndrome.
190 Martin Björck et al.Bleeding is the main complication of thrombolytic therapy,
with major bleeding (requiring intervention or blood trans-
fusion) affecting 8%e 10%of thepatients.14,130,131 Bleedingat
the arterial access site is the most common bleeding compli-
cation.To prevent this it is important to secure the sheath and
to immobilise the groin during thrombolytic therapy. Early
detection of minor bleeding complications can prevent them
becomingmajor. Interventions such as directmanual pressure,
catheter repositioning, or changing to a larger sheath can
prevent continued groin bleeding. If there is major bleeding,
thrombolysis should usually be stopped. In special circum-
stances minor bleeding may be managed, and thrombolysis
continued (possibly at a lower dose) to salvage the limb.132
Distal embolisation can occur while crossing the occlu-
sion with a wire or catheter. Embolisation can also occur
during an infusion, and may make the limb more severely
ischaemic. Experience is needed to decide whether to
continue the infusion at that stage, perhaps to increase the
dose and hope the embolus will lyse, or to stop the infusion
and adopt an open surgical or other endovascular approach.
The course of action will depend on previous progress with
lysis, and the state of the patient.133
Thrombolysis often takes time, and ischaemia may
progress during thrombolytic treatment if the clot is not
lysed. Accurate clinical evaluation of the limb is important
at baseline, with regular review during infusion. If there is
any sign of deterioration in the condition of the limb, or no
improvement on angiography over 6 e 12 hours, a change
in treatment strategy should be considered.Recommendation 30
It is recommended that patients undergoing thrombolytic
treatment for acute limb ischaemia should be monitored for
vital signs, access site complications, and the condition of
the limb.
Class Level References
I C Darwood et al. (2018),130 Wang
et al. (2016),131 Ebben et al.
(2019)14
Recommendation 31
For patients treated for acute limb ischaemia, it is
recommended that thrombolysis be stopped if major
bleeding occurs during treatment.
Class Level References
I C Darwood et al. (2018),130 Wang
et al. (2016),131 Ebben et al.
(2019)14
Recommendation 32
For patients treated for acute limb ischaemia who have minor
bleeding during thrombolysis, continued treatment should
be considered, after evaluation of the risk and benefit of
stopping or continuing.
Class Level References
IIa C Kuoppala et al. (2008),134 Grip
et al. (2014)253.6. Other endovascular techniques
Several additional percutaneous techniques have been
described for the treatment of ALI, including mechanical
thrombolysis, ultrasound assisted thrombolysis, thrombus
fragmentation, thrombo-aspiration, angioplasty, and
covered stenting.135 Technical success rates, when com-
bined with adjunctive techniques, vary from 70% to
100%.135 The potential advantage of these devices is speedy
restoration of blood flow in the ischaemic limb.136 RCTs
comparing percutaneous thrombectomy (by any means)
with thrombolysis are not available.137
3.6.1. Thrombus aspiration. The first reports of aspiration
thrombo-embolectomy described the use of simple large
bore (guiding) catheters.138 Aspiration was done using a 50
mL syringe, usually with a detachable haemostatic valve
(Fig. 7).
Several commercial aspiration catheters are now avail-
able, typically allowing end hole aspiration. A rapid ex-
change system commonly used in the coronary vessels can
be used for clot in the below knee arteries.139 There is also
an aspiration pump with specifically designed catheters
(Indigo; Penumbra, Alameda, CA, USA).140e144 The vacuum
pump uses the direct aspiration first pass technique used in
neuro-interventional procedures, where the catheter is
allowed to engage the thrombus for a short interval and
subsequently withdrawn by retracting the catheter
(Fig. 8).143 Use of adjunctive therapy should be anticipated
(thrombolyisis, angioplasty with or without stent place-
ment). A mismatch between the size of the catheter and
arterial diameter is the main reason for not achieving
complete clot removal. Incomplete removal is more
frequent in the above knee vs. the below knee arteries.142
Aspiration techniques are considered to work better when
the thrombus is acute (< 14 days old), and when larger
bore catheters can be used.145 Aspiration may also beA BA B
Figure 7. (A) Angiogram showing an embolic occlusion of the
below knee popliteal artery and tibioperoneal trunk. (B) Result
after aspiration.
A B
D
C
Figure 8. (A, B) Digital subtraction angiography showing an
acute femoropopliteal stent occlusion. (C) Result after vacuum
assisted thrombo-aspiration and balloon angioplasty of underly-
ing stenosis, demonstrating absence of residual stenosis. (D)
Thrombotic material removed with vacuum assisted thrombus
aspiration.
Recommendation 33
For patients with acute limb ischaemia, aspiration and
mechanical thrombectomy should be considered.
Class Level References
IIa C Kwok et al. (2018),141 Zehnder
et al. (2000),147 Byrne et al.
(2014),148 Kronlage et al.
(2017)152
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 191effective after failed thrombolysis.143,146 First line use of
aspiration thrombectomy can reduce the need for CDT,
without increasing costs.141,147
3.6.2. Endovascular mechanical thrombectomy. Several
mechanical thrombectomy devices are available commer-
cially. They can be classified according to their working
mechanism: rheolytic catheters or microfragmentation
catheters.136
A study that compared CDT with or without pharmaco-
mechanical thrombolysis (PMT) using the Angiojet device
showed that PMT increased technical success rates, but at
the cost of more distal embolisation.148 A matched cohort
analysis comparing PMT alone and PMT with thrombolysis
showed better outcomes, shorter procedures, and compa-
rable limb salvage in the PMT alone group. The limitation of
PMT is the inability to use the device in small calibre ar-
teries in the leg, and the risk that haemolysis may lead to
hyperkalaemia, haemoglobinuria, and renal damage.
The Rotarex system (Straub, Wangen, Switzerland) has
been studied in several registries. It has a high technical
success rate, and can reduce the need for additional cath-
eter directed thrombolysis.149e151 A comparative (non-
randomised) study of Rotarex vs. thrombolysis showed
similar technical results but better primary and secondary
patency rates with fewer complications and shorter hospital
stay in the Rotarex group.152 This device can also aspirate
more organised clot but cannot be used in smaller arteries
below the knee.153 Vessel perforation has been described
as a device related complication.153 One study reported
that re-thrombosis was more frequent after Rotarex wasused for bypass graft thrombosis, longer arterial occlusions,
and in the presence of poor runoff.154
3.6.3. Ultrasound accelerated thrombolysis. Ultrasound has
been used to accelerate thrombolysis. High frequency, low
intensity ultrasound can speed enzymatic clot lysis in vitro
by loosening fibrin strands and thereby increasing thrombus
permeability and exposing more plasminogen receptors for
binding. A RCT compared endoluminal ultrasound acceler-
ated thrombolysis (EKOS EndoWave system; EKOS, Bothell,
WA, USA) along with local urokinase vs. standard local
urokinase infusion alone (see Table 10).155 Thrombolysis
was accelerated; however, there were three (10.7%) tech-
nical ultrasound catheter placement failures. Two (7.1%)
intracranial haemorrhages, one of which was fatal, occurred
after ultrasound accelerated thrombolysis. The need to
withdraw the ultrasound co-axial wire out of the multilu-
men thrombolysis delivery catheter during control angiog-
raphy, with manipulation of the introducer sheath, seemed
to increase the risk of bleeding. In other studies using the
EKOS system, time to full flow restoration and the amount
of thrombolytic agent used was reducaed signifi-
cantly.156,157 A (non-randomised) comparison of mechanical
thrombectomy (Rotarex) and ultrasound assisted throm-
bolysis showed a higher technical success and shorter
treatment in the mechanical thrombectomy group.158
All mechanical thrombectomy devices can cause embo-
lisation of both large and small particles. The use of distal
embolic protection devices has been considered but not yet
advocated. It should be remembered that many of these
devices were originally developed for deep vein thrombosis,
a situation when minor embolisation has less serious
consequences.
The costs of all these endovascular devices are significant in
comparison to CDT alone, and it is unclearwhether the shorter
thrombolytic treatment may make the devices more cost
effective.3.7. Randomised trials for the treatment of acute limb
ischaemia
Over the years, a large number of RCTs have been done to
explore the optimal role of thrombolysis in the manage-
ment of ALI. Initially, there were several large trials done
directly comparing thrombolysis with surgery (Table 6).
Subsequently, most trials have been smaller and have been
concerned with variations in thrombolytic techniques or
agents. A summary with Forest plot figures of the results of
several meta-analyses are found in Appendix S2 (see
Supplementary Material).
Table 6. Randomised controlled trials comparing thrombolysis with surgical revascularisation
Reference Patients
n
Thrombolytic
agent
Amputation free
survival at one
year
n (%)
Major bleeding at
30 days
n (%)
Stroke at 30 days
n (%)
Distal
embolisation
at 30 days
n (%)
Nilsson et al.
(1992)160
20 High dose rtPA;
30 mg/3 h
continuous UFH
NR 0 vs. 0 0 vs. 0 1/11 (9)
vs. 0/9 (0)
Ouriel et al.
(1994)161
114 Urokinase;
continuous UFH
43/57 (75)
vs. 30/57 (53)*
6/57 (10)
vs. 1/57 (2)
1/57 (2)
vs. 0/57 (0)
5/57 (9)
vs. 0/57 (0)*
Ouriel et al.
(1996)301
213 Urokinase;
continuous UFH
107/155 (69)
vs. 38/58 (66)
60/155 (38.7)
vs. 17/58 (30)y
3/155 (1.9)
vs. 0/58 (0)
NR
Ouriel et al.
(1998)159
544 Urokinase;
continuous UFH
177/272 (65.1)
vs. 191/272 (70.2)
32/272 (11.8)
vs. 14/272 (5.1)*
4/272 (1.5)
vs. 0/272 (0)*
36/272 (13.2)
vs. 0/272 (0)*
The STILE trial
(1994)91
393 High dose rtPA;
0.05 mg/kg/h
or urokinase
continuous UFH
NR 14/249 (5.6)
vs. 1/144 (0.7)*
3/249 (1.2)
vs. 0/144 (0)
NR
Data are n (%) unless otherwise stated. rtPA ¼ recombinant tissue plasminogen activator; UFH ¼ unfractionated heparin; NR ¼ not reported.
* Significant difference.
y Need of blood transfusion.
192 Martin Björck et al.3.7.1. Surgery vs. local thrombolysis. The large and small
trials during the 1990s all agree that overall, local intra-
arterial thrombolysis and surgery were equivalent treat-
ment options for ALI in terms of amputation free survival up
to one year (Table 6).91,101,159e161 A meta-analysis of five
RCTs suggests that thrombolysis was associated with more
bleeding complications, including haemorrhagic stroke and
distal embolisation. The higher risks of bleeding with
thrombolysis should be balanced against the risks of surgery
in each patient.130 There was substantial heterogeneity
between included studies in the meta-analysis. It might be
argued that the results of these RCTs from the 1990s may
not apply to current patients with ALI,85 but it is unlikely
they will be repeated on such a large scale.
The STILE trial was the first large RCT of thrombolysis vs.
surgery for ALI, but two thirds of the patients had stable
ischaemia with a symptom duration > 14 days.91 There was
also a high rate of failed catheter placement (28%),91 similar
to the earlier Rochester study (17%).161 Even in TOPAS II,
the last major RCT of surgery vs. thrombolysis for ALI, the
rate of thrombo-embolic clot guidewire traversal failure was
11%,159 much higher than current practice. Since the 1990s,Table 7. Randomised controlled trials comparing high vs. low dose
Reference Patients
n
Thrombolytic regimen Amp
surv
n (%
Yusuf et al.
(1995)162
18 High dose pulse spray infusion
vs. low dose infusion
100 v
Braithwaite et al.
(1997)109
93 Initial repeated
intrathrombotic bolus + high
dose vs. low dose infusion
39/4
vs. 37
Plate et al.
(2006)38
121 Initial pulse spray high dose
infusion + continuous UFH
vs. low dose infusion plus
continuous UFH
49/5
vs. 54
Data are n (%) unless otherwise stated. NR ¼ not reported; UFH ¼ unfracthere has been a rapid evolution of vascular imaging,
endovascular equipment, techniques, and skills that has
driven the endovascular revolution for all vascular therapy.
In a modern endovascular practice, patients with ALI can be
offered a full range of surgical and endovascular options. In
a contemporary, large, nationwide, propensity matched
cohort comparing primary endovascular with open revas-
cularisation for ALI, endovascular revascularisation (throm-
bolysis in most patients) was associated with a higher
amputation free survival rate at 30 days (87.5% vs. 82.1%)
and at one year (69.9% vs. 61.1%).23
3.7.2. Comparison of thrombolytic regimens. Thrombolysis
may be accelerated by increasing the dose of thrombolytic
drug or altering the method of administration. An initial bolus
of rtPA (15mg), followed by infusion (3.5mg/hour for the first
four hours, then 1 mg/hour thereafter) significantly acceler-
ated thrombolysis compared with a low dose infusion without
comprising the outcome.109 A pulse spray device to lace the
entire thrombus with high dose rtPA also achieves faster
thrombolysis than a slow low dose infusion.38,162 Some 35%
(n¼ 20/58) could be treated within two hours in one series.38intra-arterial recombinant tissue plasminogen activator
utation free
ival 30 d
)
Major
bleeding
n (%)
Stroke
n (%)
Distal
embolisation
n (%)
s. 67 0 vs. 0 0 vs. 0 NR
9 (80)
/44 (84)
3/49 (6)
vs. 3/44 (7)
0/49 (0)
vs. 1/44 (2)
3/49 (6)
vs. 2/44 (4)
8 (84)
/63 (86)
4/58 (7)
vs. 8/63 (13)
2/58 (3)
vs. 0/63 (0)
10/58 (17)
vs. 8/63 (13)
tionated heparin.
Table 8. Randomised controlled trials comparing high dose vs. low dose intra-arterial urokinase
Reference Patients
n
Thrombolytic regimen Amputation free
survival 30 d
n (%)
Major
bleeding
n (%)
Stroke
n (%)
Distal
embolisation
n (%)
Cragg et al.
(1991)123
63;
72 thrombolytic
procedures
High dose bolus + high
dose infusion vs. low dose
bolus + low dose infusion
30/35 (86)
vs. 36/37 (97)*
2/35 (6)
vs. 0/37 (0)
0/35 (0)
vs. 0/37 (0)
1/35 (3)
vs. 2/37 (5)
Kandarpa et
al. (1993)163
25 High dose pulse spray vs.
initial pulse spray bolus +
continuous infusion
10/12 (83)
vs. 11/13 (85)
3/12 (25)
vs. 1/13 (8)
1/12 (0)
vs. 0/13 (0)
5/12 (42)
vs. 5/13 (38)
Data are n (%) unless otherwise stated.
* Six (five in the high dose group) exhibited progression of ischaemia. Five of the six eventually had major amputations. One patient died (not
amputated), unclear in which group. Local recombinant tissue plasminogen activator vs. urokinase.
Table 9. Randomised controlled trials comparing intra-arterial urokinase with intra-arterial recombinant tissue plasminogen
activator
Reference Patients
n
Thrombolytic agents Major amputation 30
days e 6 months
n (%)
Major bleeding
n (%)
Meyerovitz et
al. (1990)165
32 Urokinase intrathrombotic bolus + infusion
vs. rtPA intrathrombotic bolus + infusion
1/16 (6) vs. 2/16 (12) 3/16 (19) vs. 5/16 (31)
Schweizer et
al. (1996)166
120 Urokinase and continuous UFH vs. rtPA
intrathrombotic bolus + infusion and
continuous UFH
2/50 (4) vs. 1/52 (2) 1/60 (2) vs. 0/60 (0)
Mahler et al.
(2001)164
234 Urokinase vs. rtPA 3/100 (3) vs. 11/124 (9) 0/110 (0) vs. 1/124 (1)
Data are n (%) unless otherwise stated. rtPA ¼ recombinant tissue plasminogen activator; UFH ¼ unfractionated heparin.
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erated techniques,109,162 although the risk of bleeding and
distal embolisation was similar (Table 7).38,109,162
3.7.2.1. Local high vs. low dose urokinase. High dose CDT
with urokinase was as effective as low dose urokinase in
terms of duration of thrombolysis and amputation free
survival (Table 8),123,163 but bleeding was more common.123
Speed of thrombolysis and initial success rates were similar
in the high dose and low dose groups.
3.7.2.2. Local recombinant tissue plasminogen activator vs.
urokinase. No difference between urokinase and rtPA in
terms of major amputation or major haemorrhage has been
shown (Table 9).164e166
3.7.3. Local vs. intravenous recombinant tissue plasmin-
ogen activator. Please see section 3.5.1.
3.7.4. Evidence on novel thrombolytic regimens.
3.7.4.1. Abciximab. Abciximab is a potent platelet inhibitor
(glycoprotein GP IIb/IIIa receptor antagonist; Reopro [Jans-
sen, Toronto, Canada]). It has been used as an adjunct to
thrombolysis in three studies. Patients with acute periph-
eral artery thrombosis were randomised to received 5 mg
rtPA intravenously and 500 IU UFH/hour, along with either
an intravenous bolus of 0.25 mg/kg abciximab followed by
10 mg/minute intravenous abciximab over 12 hours, or 500
mg acetylsalicylic acid (ASA).167 The abciximab group had a
significantly lower composite of adverse events (sum ofrates of rehospitalisation, re-interventions, and amputa-
tions) at six months compared with the ASA group. One
major bleed (fatal haemorrhagic stroke) occurred in the ASA
group. No distal embolisation occurred in either group
(Table 10). A second RCT including patients with both
thrombotic and embolic occlusions treated with local uro-
kinase plus intravenous abciximab vs. local urokinase plus
placebo168 showed faster thrombolysis and a higher
amputation free survival at 90 days (96% vs. 80%) without
an increase in bleeding complications in the urokinase plus
abciximab group (Table 10); this was the dominant strategy
at three months.169 In a third RCT,121 reteplase, a third
generation thrombolytic agent, plus intravenous abciximab,
was not superior to urokinase plus intravenous abciximab in
terms of reduced amputation rates (Table 10). During the
three year follow up, only two patients (1.7%) underwent
major amputation, which, according to the authors, may
have been attributed to abciximab.
3.7.4.2. Alfimeprase. Alfimeprase is a recombinant protein of
the enzyme fibrolase, a zinc metalloprotease originally isolated
from the venom of the southern copperhead snake. Alfime-
prasedirectlydegradesfibrin alpha chain andhasno interaction
with plasminogen. In one study, intrathrombus alfimeprase (0.3
mg/kg) in two divided weight based infusions two hours apart
was no more effective than intrathrombus placebo in 30 day
surgery free survival,whereas the overall rate of adverseevents
was higher with alfimeprase (Table 10).170
Table 10. Single randomised trials comparing different thrombolytic regimens
Reference Patients
n
Thrombolytic regimens Amputation
free survival
n (%)
Major
bleeding
n (%)
Stroke
n (%)
Distal
embolisation
n (%)
Schrijver et al.
(2015)155
60 Ultrasound accelerated
thrombolysis + local
urokinase vs. standard
urokinase infusion
NR 3/28 (11)
vs. 2/32 (6)
2/28 (7)
vs. 0/32 (0)
1/28 (4)
vs. 0/32 (0)
Schweizer et al.
(2000)167
84 5 mg rtPA IV and 500 IU
heparin/h, + either
500 mg ASA or an IV bolus
of 0.25 mg/kg abciximab
followed by 10 mg/min
abciximab IV for 12 h
37/42 (88)
vs. 40/42 (95)
at 6 mo
1/42 (2)
vs. 0/42 (0)
1/42 (2)
vs. 0/42 (0)
0/42 (0)
vs. 0/42 (0)
Duda et al.
(2001)168
70 Local urokinase + IV
abciximab vs. local
urokinase + placebo
48/50 (96)
vs. 16/20 (80)
at 90 d
4/50 (8)
vs. 0/20 (0)
0/50 (0)
vs. 0/20 (0)
3/50 (6)
vs. 2/20 (10)
Tepe et al.
(2006)121
120 Reteplase + IV abciximab
vs. urokinase + IV
abciximab
NR 5/50 (10)
vs. 4/70 (6)
0/50 (0)
vs. 0/70 (0)
11/50 (22)
vs. 6/70 (9)
Han et al.
(2010)170
398 Intrathrombus alfimeprase
(0.3 mg/kg)
vs. intrathrombus placebo
NR 10/199 (5)
vs. 6/199 (3)
1/199 (0.5)
vs. 0/199 (0)
20/199 (10.0)
vs. 5/199 (2.5)*
Ouriel et al.
(1999)124
228 Recombinant
pro-urokinase
vs. standard therapy
with urokinase
57/61 (93)
vs. 47/55 (85)
vs. 45/52 (86)
vs. 50/60 (83)
at 30 d
9/61 (15)
vs. 11/55 (20)
vs. 12/52 (23)
vs. 10/60 (17)
0/61 (0)
vs. 0/55 (0)
vs. 0/52 (0)
vs. 0/60 (0)
12/61 (20)
vs. 11/55 (20)
vs. 8/52 (15)
vs. 6/60 (10)
Poredos and
Videcnik
(1999)171
88 Local streptokinase
infusion  lacing
of plasminogen into
the thrombus
6/43 (14)
vs. 8/45 (18)
7/43 (16)
vs. 5/45 (11)
0/43 (0)
vs. 0/45 (0)
4/43 (9)
vs. 6/45 (13)
Data are n (%) unless otherwise stated. NR ¼ not reported; rtPA ¼ recombinant tissue plasminogen activator; IV ¼ intravenous; IU ¼
international units; ASA ¼ acetylsalicylic acid; h ¼ hours; min ¼ minutes; mo ¼ months; d ¼ days.
* Significant difference.
194 Martin Björck et al.3.7.4.3. Pro-urokinase. Recombinant pro-urokinase is a sin-
gle chain zymogen that is assembled into active two chain
urokinase on the surface of the thrombus. This plasminogen
activator is a highly fibrin specific agent. In an RCT, four
regimens were compared: recombinant pro-urokinase (2 mg/
hour, 4 mg/hour, or 8 mg/hour, followed by 0.5 mg/hour in
all three arms) vs. standard therapy with urokinase.124 The
patients receiving pro-urokinase responded in a dose
dependent manner, resulting in a higher frequency of > 95%
clot lysis and a lower frequency of < 25% clot lysis at eight
hours for those receiving 8 mg/hour compared with the
other regimens, accompanied by a non-significant increase in
bleeding complications. There was no difference in amputa-
tion rates between the four regimens (Table 10).
3.7.4.4. Enrichment with intrathrombus plasminogen. One
RCT compared local streptokinase infusion after deposition
of plasminogen into the thrombus vs. local streptokinase
(Table 10).171 While the duration of thrombolysis was
shorter in the former group, there was no difference in
successful thrombolysis rates between the groups.
3.8. Primary open surgery or thrombolysis for acute limb
ischaemia?
ACochraneReviewaddressed thequestion ofwhether surgical
or thrombolytic therapy should be the preferred initial treat-
ment of ALI.130,172 Five RCTswith a total of 1 283 patients wereincluded. The authors concluded that a general recommen-
dation for initial treatment of ALI cannot be made for open
surgery or thrombolysis, based on the current scientific data.
There were no significant differences in limb survival or death
between the two treatments after 30 days, six months, or one
year. After 30 days, the thrombolysis group had a larger
number of haemorrhagic strokes, major bleeding, and epi-
sodes of distal embolisation (see Table 6).Yet, these risks must
be balanced against the individual risks of surgery, especially as
there was no difference in long term survival. Another recent
systematic review reported similar results, with no evidence in
favour of either thrombolysis or surgery.11
The risks of surgery and thrombolysis in the initial
treatment of ALI are presented in a meta-analysis. This
analysis also supplies the background for the medical
guidelines of the American College of Chest Physicians.60
A retrospective comparison between endovascular (154 ex-
tremities) and surgical (316 extremities) revascularisation for
ALIwasperformed.103 ForRutherfordgrade II ischaemia, results
were as follows: technical success 90.7% (surgery) vs. 79.9%
(endovascular); major amputation rate after 30 days 10.0%
(surgery) vs. 7.2% (endovascular); and after one year 16.3%
(surgery)vs.13%(endovascular).Thirtydaymortalitywas13.2%
after surgery and5.4%afterendovascular revascularisation.The
authors concluded that in ALI with Rutherford grade II
ischaemia, endovascular revascularisation could provide similar
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 195limb survival to surgery, but with lower mortality. These results
were confirmed in a propensity score matched analysis of a
large contemporary cohort study (see section 3.9.1).
One study reported 322 patients with ALI, who received
either surgical embolectomy alone (n ¼ 112), or embolec-
tomy in combination with an endovascular procedure (n ¼
210).72 In addition to embolectomy, these hybrid proced-
ures included percutaneous transluminal angioplasty (PTA)
 stenting (n ¼ 90), direct CDT þ PTA  stenting (n ¼ 24),
and fragmentation / aspiration of the thrombus þ PTA 
stenting in 67 patients. Primary patency rates after five
years were 87.1% (hybrid procedure) vs. 66.3% (embolec-
tomy). Freedom from re-intervention was estimated at 89%
vs. 73.7%. The authors of this paper concluded a hybrid
approach has advantages in selected patients.723.9. Specific considerations
3.9.1. Long term outcomes after acute limb ischaemia.
Knowledge on the impact of revascularisation technique on
long termoutcomes is scarce. So far, no randomised study has
evaluated long term mortality, patency, or amputation rates.
The largest retrospective epidemiological analysis of treat-
ment of ALI was based on data from the NHDS in the USA.18
The authors included 1 092 811 hospital admissions for acute
arterial embolism or thrombosis of the leg from1988 to 1997,
but no long term follow up data were reported.
Trends in the treatment of ALI in the Medicare popula-
tion of the USA were also analysed from 1998 to 2009,24
including one year follow up. One year mortality
remained unchanged (41.0% vs. 42.5%), but the amputation
rate at one year decreased from 14.8% to 11.0%.76
In a retrospective study from the Swedish Vascular Registry,
3 365 patients who underwent endovascular treatment were
compared with 3 365 patients who underwent open surgery
for ALI below the inguinal ligament after propensity score
matching.23 At 30 days, the endovascular group had better
patency (83.0% vs. 78.6%) and lower mortality rate (6.7% vs.
11.1%), but amputation rates were similar. Five years after
surgery, endovascular treatment still showed improved sur-
vival (HR 0.78, 99% CI 0.70 e 0.86), although the difference
between the two groups occurred mainly in the first year.
Another paper reported the long term follow up of 689
patients who underwent thrombolysis for ALI.26 During aA B
Figure 9. (A) Thrombosed popliteal artery aneurysm (PA). (B) Opened Pmean follow up of five years, 33% needed further re-
interventions, 16% underwent amputation, and 51% had
no re-intervention. There were large differences in need for
re-intervention, primary patency, amputation, and survival,
depending on the cause of ALI. The amputation rate was
lowest after embolus, survival was highest after occluded
PA, and amputation free survival was lowest after occluded
graft / stent, all at five years.
In an international collaboration between two centres in
Finland and Russia, 155 patients treated by CDT for grade I
or IIa ischaemia were studied with a mean follow up of 126
months.173 Only 30% were alive after 10 years; AF and older
age were associated with mortality. Re-interventions were
common: 190 additional procedures in 122 patients.
3.9.2. Aetiology of the occlusion. Differences in outcome
are dependent on the aetiology of the occlusion: arterial
thrombosis, embolus, aneurysm, or graft thrombosis.
In the Rochester trial,161 irrespective of whether the ALI
was caused by embolic or thrombotic occlusion, surgery
and thrombolysis were equally effective for limb salvage.
However, the one year survival rate appeared greater when
patients with embolic events were treated by thrombolysis
(100% vs. 51%). The benefit for patients with thrombotic
occlusions was less substantial.
In the TOPAS trial,159 subgroup analysis showed that
surgery and thrombolysis provided comparable outcomes in
patients with native arterial occlusion, as well as in those
with bypass graft thrombosis. Patients with emboli
randomly assigned to initial thrombolysis tended to have
improved thrombolysis rates and less need for secondary
intervention.
In the STILE trial, patients with acute graft occlusion (< 14
days) had the greatest benefit from thrombolysis.91,100 There
was a trend toward a lower major amputation rate at 30
days, and a significantly lower rate at one year compared
with those who had surgery. In the recent Swedish Vascular
Registry study,23 amputation free survival was higher after
primary endovascular intervention, irrespective of whether
the ALI was caused by embolus or thrombosis.
Collectively, these trials suggest that thrombolysis may
have an advantage for the treatment of acute bypass graft
occlusions, with initial success rates tending to be better for
prosthetic than vein grafts.C
A showing thrombus. (C) Reconstruction with a doubled vein graft.
Recommendation 35
For patients with acute limb ischaemia secondary to popliteal
artery aneurysm, pre-operative or intra-operative
thrombolysis to improve runoff should be considered.
Class Level References
IIa B Ravn et al. (2007),178 Gabrielli
et al. (2015)179
Recommendation 34
For patients with acute limb ischaemia secondary to
thrombosis of a popliteal artery aneurysm, repair of the
aneurysm with a saphenous vein bypass should be considered.
Class Level References
IIa B Huang et al. (2014),180 Cervin et
al. (2015)176
196 Martin Björck et al.3.9.3. Length of occlusion. Data from the TOPAS trial were
analysed using a Cox proportional hazard multifactorial
model to determine whether baseline variables could be
useful in deciding whether patients should be treated by
thrombolysis or surgery.101 The length of occlusion was the
only parameter to be significant. Patients with an occlusion
of < 30 cm appeared to do better after surgery, with an
increased one year amputation free survival rate (79% vs.
60%). Patients with occlusions > 30 cm tended to fare
better after thrombolysis, with an improved one year
amputation free survival (69% vs. 61%).
3.9.4. Acute limb ischaemia due to popliteal artery aneu-
rysm. PA may cause ALI by thrombosis and / or embolisa-
tion. Distal embolisation may occur to one, two, or all three
major lower leg arteries, leading to chronic or acute limb
ischaemia. In the latter case the limb may be ischaemic, but
with a patent popliteal artery. If the popliteal artery
thromboses, leg ischaemia may be mild if distal vessels are
preserved, but more often it is severe, as the distal vessels
are already occluded. A recent study of 55 patients with ALI
due to PA, treated by open surgery, reported that it may be
difficult to distinguish grade IIb and grade III ischaemia in
these patients.174 A systematic review reported a high risk
of amputation after acute thrombosis of a PA (14.1%).175
Although femoral and iliac artery aneurysms may cause
thrombo-embolism and ALI, this is much less common and
will not be discussed in these guidelines.
The diagnosis of PA as the cause of ALI is often clinical, as
the aneurysm may be palpable if it has not thrombosed
completely, and about half the patients have bilateral PAs.
The diagnosis is confirmed by imaging with DUS or CTA. The
state of the tibial vessels is critical in management, as the
patency of a surgical bypass is dependent on the number of
patent tibial arteries. Surgical bypass has been the mainstay
of treatment, but endovascular stenting with a covered stent
graft is a more recent alternative. Surgical bypass should be
done with saphenous vein where possible, as patency rates
vs. prosthetic bypass are superior after one year .176 The
popliteal artery may be exposed by medial or posterior ap-
proaches. A meta-analysis of seven comparative, non-
randomised studies including 338 patients undergoing pos-
terior and 1 089 undergoing medial open bypass included a
majority of elective repairs. The posterior approach was su-
perior in terms of primary and secondary patency, aneurysm
exclusion, and need for re-operation,177 although it was more
often done for short lesions (Fig. 9). Extrapolation of these
data to patients with acute ischaemia is not appropriate.
3.9.4.1. The role of thrombolysis in popliteal artery aneu-
rysm with acute limb ischaemia. Adjuvant intra-arterial
thrombolysis may be valuable in patients with ALI due to
PA thrombosis. Unlike native vessel thrombosis, the aim of
peripheral arterial thrombolysis is not to re-open the whole
artery, as this risks catastrophic distal embolisation,133 but to
re-open occluded tibial vessels to optimise the potential for
surgical bypass.178 Once partial lysis is achieved, there is an
option to continue with endovascular therapy and end thetreatment session by placing a stent graft; however, once the
distal vessels are patent, most surgeons employ an open vein
bypass, particularly if there is a good saphenous vein available
in either leg. Alternatively, thrombolytic drugs may be given
intra-operatively after popliteal artery exploration in an
attempt to re-open tibial vessels occluded by fresh thrombus,
before inserting a distal bypass. Intra-operative thrombolysis
has been reported to improve limb salvage vs. pre-operative
thrombolysis and delayed surgery in a univariable analysis.179
In a systematic review of 33 studies including 895 patients,
pre-operative and /or intra-operative thrombolysis improved
one year primary graft patency, but did not reduce the risk of
amputation compared with surgery (thrombo-embolectomy
and bypass) alone.175 In registry data, thrombolysis for PA
was associated with the need for higher doses of rtPA, more
bleeding complications needing blood transfusion, a higher
fasciotomy rate, a higher major amputation rate at 30 days
and lower amputation free survival compared with throm-
bolysis for ALI due to native vessel or bypass occlusion. The
authors concluded this was due to the higher rates of severe
ischaemia with a motor deficit at presentation.25
3.9.4.2. The role of covered stenting in popliteal artery
aneurysm with acute limb ischaemia. Endovascular lining
with a covered stent is an option to seal the inside of the
popliteal artery as an alternative to surgical bypass. There are
no RCTs comparing open surgerywith stenting with orwithout
thrombolysis for ALI secondary to PA. Two reports describe
outcomes after vein bypass vs. endovascular PA repair in pa-
tients treated urgently for ALI.176,180 The pooled 30 day graft
occlusion and amputation rate was higher after endovascular
stenting than after open vein repair. A nationwide study using
the Swedish Vascular Registry suggests compromised runoff is
common even after tibial thrombo-embolectomy or local
thrombolysis for thrombosed PA, leading to a low flow situa-
tion, which contributes to the inferior performance of pros-
thetic grafts and stent grafts, comparedwithvein grafts.176 The
two most important factors in multivariable analysis for major
adverse events in the mid term after PA repair were fewer
patent runoff arteries to the foot and endovascular repair.180
Recommendation 36
For patients with acute limb ischaemia secondary to popliteal
artery aneurysm, stent grafting is not recommended as first
line treatment.
Class Level References
III B Huang et al. (2014),180 Cervin et
al. (2015)176
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 1973.9.5. Management of compartment syndrome and
reperfusion injury
3.9.5.1. Pathophysiology. IRI is the consequence of flow
restoration to ischaemic tissue. Tissue damage is initiated in
the ischaemic phase but continued, and even aggravated after
reperfusion. IRI involves a number of mechanisms, such as the
release of oxygen free radicals and infiltration of neutrophils
into the reperfused tissues.181 This provokes vasodilation and
capillary leakage, resulting in tissue oedema. Recent research
has concentrated on potential IRI biomarkers; these include
matrix metalloproteinases, neutrophyl gelatinase associated
lipocalin, and inflammatory cytokines.182
Compartment syndrome (CS) is a serious complication
following ALI revascularisation.The tissue swelling as a result of
IRI raises pressure in the limbmuscles which are constrained by
fascial compartments.Thus, intracompartment pressure rises as
a result of swelling and may be sufficiently high to reduce
perfusion of already damaged tissues. Untreated, the extremity
(usually the foot)becomes ischaemic again, and the limbmaybe
lost, despite previously successful revascularisation. Late diag-
nosis and treatmentare associatedwith severemorbiditydue to
irreversible muscle necrosis and ischaemic nerve damage.
3.9.5.2. Incidence. CS can occur after any revascularisation for
ALI: embolectomy, thrombolysis, or bypass surgery.183 How-
ever, it is more common after revascularisation of prolonged,
severe ischaemia. Ahigh incidenceofCS (up to25%e30%)has
been reported in several studies.184,185 Themain complication
is leg amputation, but deaths do occasionally occur.
3.9.5.3. Diagnosis. The diagnosis of CS is usually based on
clinical symptoms and signs; however, they have poor sensi-
tivity, which may result in delayed diagnosis.186 Pain is usually
present and is often severe, but it is an unreliable indicator as
its intensity can be variable. Pain may be minimal in CS asso-
ciatedwithnerve injury. Swelling and tenderness of themuscle
compartments are signs, which should suggest the diagnosis,
although a haematoma may be an alternative explanation.
Sensory symptomsand signs are oftenpresent in the extremity
at an early stage, but by the time a motor deficit develops, full
recovery is unusual, being reported in only 13% of patients.187
CS caused by IRI results in muscle damage, accompanied
by leakage of myoglobin and CK into the circulation (rhab-
domyolysis). Excretion of myoglobin in the urine (myoglo-
binuria) can cause renal tubular damage and renal failure, in
extreme cases.188 CK can be measured in the blood and
high levels (5 000 e 10 000 IU/L) are indicative of severe IRI
and CS, with the potential for acute renal failure.189,190
Rhabdomyolisis is diagnosed once CK reaches 20 000 m/L.
Raised CK occurs relatively late in CS, so it is not very useful
for early diagnosis. Other biochemical markers includeneutrophil to lymphocyte ratio; a ratio of > 5 is associated
with higher mortality rates after ALI.191,192
Compartment pressure measurement is straightforward
using a needle manometer, but there is little consensus about
the threshold value fordiagnosis and treatment of CS. Elevated
compartment pressure above 20 e 30 mmHg has high sensi-
tivity and specificity (94% e 98%) for CS, but some authors
believe the absolute value should be related to mean arterial
pressure at the time.193,194 Compartment pressure is seldom
measured routinely;194,195 indeed routine measurement after
reperfusion may even result in overtreatment.196
Several authors have attempted to identify risk factors
for the development of CS, including ischaemia duration >
6 hours, young age, previous history of ALI, and hypoten-
sion.197 Others found that elevated serum CK, severity of
acute ischaemia (Rutherford IIb), inadequate intra-operative
backflow and positive fluid balance were associated with CS
after ALI treatment.184 The importance of these findings lies
in the possibility of identifying patients who would benefit
from immediate fasciotomy after revascularisation for ALI,
or at least undergo close monitoring post-operatively, and
delayed fasciotomy if necessary.
3.9.5.4. Prevention of compartment syndrome. Slow
restoration of the circulation (controlled limb reperfusion)
has been extensively investigated to try and reduce IRI. It is
thought that thrombolysis might offer this compared with
surgical revascularisation. After initial optimistic results,198 a
recent RCT failed to find an improvement in amputation free
survival or overall survival at four weeks and one year vs.
conventional treatment for ALI.199 Hypothermic, initially ox-
ygen free, controlled limb reperfusion with extracorporeal
membrane oxygenation (ECMO) is another possible solution,
although not widely available,185 and poorly investigated.
The main way to prevent CS is to conduct prophylactic
fasciotomy after revascularisation. Obviously, this is an easier
option for patients who have have had surgical treatment,
but must be considered after all urgent revascularisation
procedures. Decisions will be individualised for each patient
but should take into account the risk factors mentioned
above. A recent study reported that patients undergoing
delayed fasciotomy were more likely to require major
amputation within 30 days than patients having prophylactic
fasciotomy (50% vs. 5.9%), suggesting that a liberal approach
to prophylactic fasciotomy was favourable.200 However, there
are many confounding factors in this comparison, including
the timing of on demand fasciotomy, making it difficult to
draw firm conclusions from these data.
3.9.5.5. Treatment. Fasciotomy is the treatment for both
established CS, and prophylaxis against possible IRI. The lower
leg is the most common location of CS. A single incision
technique over the anterior compartment was advocated,201
but this risks leaving the posterior compartments untreated
and ischaemic. A full four compartment fasciotomy is the
current standard of care, which is typically achieved with two
incisions (Fig. 10). The compartments must be decompressed
fully, which requires skin incisions of at least 15 cm in length.
Thewounds should be left open, as early closure of fasciotomy
wounds has been associated with recurrent CS. Various
A B C D
Figure 10. Fasciotomies of the leg: a full four compartment fasciotomy is recommended, which is typically
achieved with two incisions. (A) Lateral incision (1 ¼ peroneal nerve). (B) Medial incision (1 ¼ great saphenous
vein). (C) Fasciotomies of the superficial posterior and deep posterior compartments (1). Fasciotomies of the
anterior and lateral compartments (2). (D) Four compartment fasciotomy, with the wounds left open (1 ¼
anterior compartment; 2 ¼ lateral compartment; 3 ¼ deep posterior compartment; 4 ¼ superficial posterior
compartment). Reproduced with permission from Ricco et al.202
Recommendation 38
Compartment pressure measurement may be considered to
diagnose post-reperfusion compartment syndrome, when
the clinical diagnosis is uncertain.*
Class Level References
IIb C Janzing et al. (2007),186
McQueen and Court-Brown
(1996)194
* Recommendation refer to the lower limb.
Recommendation 39
For patients who have had revascularisation for acute limb
ischaemia, routine prophylactic fasciotomy is not
recommended, as it is associated with prolonged hospital
stay, local infection, and development of late deep venous
insufficiency.*
Class Level References
III C Bermudez et al. (1998),206
Johnson et al. (1992)205
* Recommendation refer to the lower limb.
198 Martin Björck et al.techniques are described for wound closure following fas-
ciotomy, including vacuum assisted wound closure, shoelace
suturing, skin stretching, and skin grafting.
Fasciotomy is needed less often in the arm (for details
please see section 7). The timing of fasciotomy is critically
important in patients who develop CS. Untreated CS com-
pounds ischaemic muscle damage, and risks myoglobinuria
and renal failure. In this situation, fasciotomy is an emer-
gency procedure, and should take precedence over most
other urgent surgical cases. Performing fasciotomy in the
intensive care or high dependency unit should be considered,
to avoid delay. Fasciotomy should usually be done within two
hours of diagnosis; waiting longer than six hours is not
acceptable. Fasciotomy should be done within eight hours of
the development of CS,203 but even that may be too late in
some patients. It is probaly too late for fasciotomy if CS has
been present for more than eight hours.204
Fasciotomy is not entirely without risk. Early skin grafting
or coverage by other means may reduce the risk of infec-
tion.205 It has also been shown that approximately half of
patients who undergo fasciotomy develop symptoms of
deep venous insufficiency, which may become more sig-
nificant with time.206 Thus, the decision to perform fas-
ciotomy should always be considered carefully.Recommendation 37
For patients who have had revascularisation for acute limb
ischaemia, clinical examination is recommended to
diagnose post-reperfusion compartment syndrome.*
Class Level References
I B Janzing et al. (2007),186McQueen
and Court-Brown (1996),194 von
Keudell et al. (2015),203
Gourgiotis et al. (2007)193
* Recommendation refer to the lower limb.
Recommendation 40
Prophylactic four compartment fasciotomy should be
considered if ischaemia before revascularisation has been
profound or prolonged.*
Class Level References
IIa C Papalambros et al. (1989),197
Orrapin et al. (2017),184
Rothenberg et al. (2019)200
* Recommendation refer to the lower limb.
Recommendation 42
When post-ischaemic compartment syndrome is diagnosed,
fasciotomy should be considered as soon as possible, and
always within two hours.*
Class Level References
IIa C Consensus
* Recommendation refer to the lower limb.
Recommendation 41
Emergency four compartment fasciotomy is recommended to
treat post-ischaemic compartment syndrome.*
Class Level References
I B von Keudell et al. (2015),203
Gourgiotis et al. (2007)193
* Recommendation refer to the lower limb.
Recommendation 43
When post-ischaemic compartment syndrome of the lower
limb is diagnosed, delaying fasciotomy by more than six
hours is not recommended.*
Class Level References
III C von Keudell et al. (2015),203
Finkelstein et al. (1996)204
* Recommendation refer to the lower limb.
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The decision making algorithm in acute limb ischaemia is
provided in Fig. 11.4. POST-OPERATIVE MEDICAL TREATMENT AND FOLLOW
UP
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Recommendation 44
After revascularisation for acute limb ischaemia, follow up
200 Martin Björck et al.indications for follow up after treatment.29,207 This may
include both the patient’s cardiovascular condition and an
assessment of the functional status of the limb. Although
ALI is an important healthcare problem, numbers of pa-
tients are limited, which, together with its acute character,
makes research more difficult. There are no RCTs comparing
different types of follow up, but data from registries and
observational studies are available.
The 2017 European Socity of Cardiology (ESC) Guidelines
on PAD developed in collaboration with the ESVS did not
specifically address issues related to patients treated for
ALI.4 However, there are general principles guiding medical
treatment and follow up after embolisation, or surgical
bypass in the lower limb. The same WC developed further
those recommendations on follow up in a subsequent 2019
publication.208Recommendation 46
After revascularisation for acute limb ischaemia caused by an
embolus secondary to atrial fibrillation or intracardiac
thrombus, long term anticoagulation is recommended.
Class Level References
I B Ljungman et al. (1991),16
Campbell et al. (2000),29
de Haro et al. (2016)212
should be considered, including the patient’s cardiovascular
condition and functional status of the limb.
Class Level References
IIa C Zierler et al. (2018),218
Campbell et al. (2000),29 Ansel
et al. (2008)207
Recommendation 45
For patients revascularised for acute limb ischaemia of
embolic origin, it is recommended that, whenever possible,
the source of the embolus be investigated, to prevent
recurrence.
Class Level References
I B Kirchhof et al. (2016),219
Gerhard-Herman et al. (2016)59
Recommendation 47
For patients who have had revascularisation for acute limb
ischaemia of embolic origin, long term anticoagulation may
be considered for patients without atrial fibrillation or
intracardiac thrombus.
Class Level References
IIb C Forbes et al. (2002)2134.1. Follow up after arterial embolisation
As the most common causes of arterial embolisation are AF
and intracardiac thrombosis, one of the most important
aims of post-operative management is the prevention of
recurrent embolisation. The source of the embolus needs to
be verified. The evaluation includes electrocardiogram
(ECG), other diagnostic methods to identify acute myocar-
dial infarction, 24 hour ECG monitoring when necessary, as
well as echocardiography and CTA of the whole aorta if no
intracardiac embolic source is identified.59
The value of AC for prevention of embolisation in patients
with AF is well established.209,210 In a large registry study
post-operative AC treatment with warfarin was associated
with a reduced risk of early limb loss after embolectomy for
acute arterial occlusion.16 The Vascular Surgical Society of
Great Britain and Ireland carried out an audit after treat-
ment for ALI. It was concluded that recurrent limb
ischaemia was less common in patients given warfarin
initially (7% vs. 17%) and still taking warfarin after one year
(3% vs. 19%).29
Warfarin has been the most commonly used medication
for this purpose for decades. A meta-analysis from 2013
reported direct oral anticoagulants (DOACs) to be no more
effective in preventing non-haemorrhagic stroke and sys-
temic embolic events in patients with AF, but they were
associated with a lower risk of intracranial bleeding than
warfarin.211 A more recent meta-analysis, from 2016, sug-
gested that DOACs may decrease the risk of ALI significantly
compared with warfarin in patients with AF.212
A review of 50 patients presenting with ALI showed that
patients without AF or intracardiac thrombus may not carry
the same risk of recurrent events as those with these risk
factors.213 Long term AC may not be necessary in this group
of patients, as there are few published data supporting this
approach. However, this area awaits a properly designed
prospective randomised trial that preferably also wouldconsider the importance of cardiac risk factors and
concomitant malignant disease.
Early heparinisation after surgery for ALI appears valu-
able, but there is no evidence of a benefit of short or long
term heparin treatment in patients with acute thrombo-
embolic arterial occlusion.61,214
Multiple studies report that many patients with AF are
not given AC treatment,215e217 and many others have
suboptimal AC levels.217 The specific treatment of AF and
other dysrhythmias is covered by the ESC guidelines.
Recommendation 48
Long term anticoagulation may be considered after
thrombectomy or endovascular treatment of a prosthetic
bypass graft occlusion.
Class Level Reference
IIb B Liang et al. (2017)231
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 2014.2. Follow up after native arterial thrombosis, or occlusion
of an artery treated by endovascular or open surgery
Patients with ALI are prone to repeated major cardiovas-
cular events, often leading to rehospitalisation, re-
intervention, and early mortality. In patients with symp-
tomatic PAD, ALI is most often caused by thrombosis of the
diseased native vessel, or by acute occlusion of a bypass
graft, or an endovascular procedure. Following surgical or
endovascular revascularisation for ALI caused by arterial
thrombosis, regular follow up may be beneficial, including
clinical evaluation and assessment of functional status,4,208
although specific studies addressing this issue were not
identified. During follow up visits, pulse examination and
ABI measurements are performed. If clinical symptoms
deteriorate, or there is a significant drop in ABI, vascular
imaging (DUS, CE-MRA, CTA, or DSA) is required.
4.2.1. Concomitant malignancy or thrombophilia. When
young patients (< 60 years of age) are affected by throm-
botic ALI, and in particular when patients suffer simulta-
neous venous and arterial thrombosis, concomitant
malignant disease220 and thrombophilia221 should be
investigated post-operatively.
4.2.2. Smoking cessation. Smoking is a strong risk factor for
the development and progression of PAD.222,223 Several
studies suggest that smoking cessation is associated with a
lower rate of cardiovascular ischaemic and limb related
vascular events, amputations, and death.224,225 Therefore,
patients who smoke should be advised to quit smoking at
every follow up visit, and should be offered support from a
smoking cessation team, if available.208,226
4.2.3. Antithrombotic medication and statins. Following
ALI revascularisation for arterial thrombosis, antiplatelet
therapy and statins should be administered to decrease
cardiac complications and to prevent atherosclerotic dis-
ease progression.227 A meta-analysis of the Antithrombotic
Trialists’ Collaboration showed that among patients with
symptomatic PAD treated with antiplatelet therapy there
was a 22% odds reduction for cardiovascular events,
including myocardial infarction, stroke, or vascular death.228
The large British Heart Protection study (2002) provided
robust evidence that statins reduce stroke, acute myocardial
infarction, and death of patients with PAD.229 In a sys-
tematic review of observational studies, statins were asso-
ciated with improved infra-inguinal bypass graft patency,
reduced restenosis, and amputation rates.230 The above
mentioned studies mainly apply to patients with chronic
PAD, but it is expected that similar benefits will also apply
to patients who developed ALI as a result of thrombosis.
There are no data showing that UFH, LMWH, or AC treat-
ment is of any benefit for the prevention of a recurrent arterial
thrombotic event. In a registry based study, it was concluded
that AC was associated with significantly improved secondary
patency in patients with prosthetic bypass grafts (HR 0.77);231
therefore, long term AC after thrombectomy or thrombolysis
of an occluded prosthetic bypass might be considered. The
combination of low dose DOAC and low dose aspirin, as in theCardiovascular Outcomes for People Using Anticoagulation
Strategies (COMPASS) trial, has not primarily been investigated
after ALI. However, in patients with stable PAD, an overall
benefit from receiving rivaroxaban2 2.5 mg plus aspirin 100
mg was demonstrated.232 A small subgroup of patients within
this study who had ALI also had a marked reduction in
amputation andmortality rate.223 Although the COMPASS trial
was positive for patients with ALI, this was not the primary end
point, and further research with a focus on ALI is needed.
4.2.4. Imaging. DUS is the imaging modality of choice dur-
ing follow up. It is non-invasive, and the most appropriate
method to evaluate degree of stenosis. There are no
problems with artefacts after stenting. CTA and CE-MRA are
alternative non-invasive tools for follow up. CE-MRA can
provide useful information on the remodelling process after
endovascular interventions and can also determine patency
and restenosis if stents were not used.233
DUS surveillance after infrainguinal vein bypass (in gen-
eral, not specifically after treatment of ALI) has been
advocated for over 20 years, however, the evidence for this
practice remains contradictory.234,235 A recent meta-
analysis showed that DUS surveillance compared with
clinical examination and ABI measurement was not associ-
ated with a significant change in vein bypass patency,
amputation, or mortality.236 Although there are no data on
optimal timing, many vascular surgeons offer clinical and
imaging follow up after four to six weeks, three and six
months, and one and two years after bypass surgery.4.3. Follow up after thrombosed popliteal aneurysm
In a registry based study it was observed that the number of
surgical procedures for PA, including thrombosed cases with
ALI, have almost doubled in Sweden over the past 10 years,
probably owing to an increased detection rate.176 Nonethe-
less, the proportion of patients with ALI due to thrombosed
PA is low. In another large registry study on ALI, only 536 of
16 229 (3.3%) patients treated for ALI had a thrombosed
PA.23 Patients with PA have an increased risk of a new
aneurysm formation in the contralateral popliteal region, the
aorta, and at other locations.237 Therefore, these patients
should be followed and if a new aneurysm develops, vascular
reconstruction should be considered to protect life and limb.
In a re-examination of 190 patients, who had another 108
aneurysms at the time of surgery, another 131 aneurysms
were identified after a mean of seven years.238 Six of 138 legs
(4.3%) treated with a venous bypass had developed a graft
aneurysm. Although the authors recommended life long
surveillance, no patient with a normal arterial segment
202 Martin Björck et al.developed an aneurysm requiring intervention within three
years. Therefore, it would be adequate to re-examine the
normal arterial segments every three years.
A similar follow up approach can be recommended after
endovascular therapy of a thrombosed PA. However, there
are no data to support DUS surveillance improving
outcome. If DUS detects a severe restenosis, endovascular
re-intervention or open surgery is recommended. In pa-
tients who undergo endovascular intervention for PA, or
open surgery with a medial approach, exclusion of the
aneurysmal sac from the blood flow should also be exam-
ined, as late expansion is common (33% after a median of
seven years of follow up in one study).238 DUS can detect
expansion of the aneurysm sac after PA repair, but CTA is
more reliable in detecting the expansion mechanism. There
is no specific study to confirm the benefit of platelet in-
hibitors and/or statins after surgery for a thrombosed PA;
however, on the basis of general observations the use of
these drugs can be expected to be beneficial.Recommendation 50
For patients treated for thrombosed popliteal artery
aneurysm, regular duplex ultrasound follow up should be
considered after open or endovascular surgery.
Class Level References
IIa B Dawsonet al. (1991),237Ravn et al.
(2008),238 Loftus et al. (1999)242
Recommendation 51
For patients treated by open or endovascular surgery for
thrombosed popliteal artery aneurysm, duplex ultrasound
imaging of the treated and contralateral arteries, as well as
of the aorta, iliac, and femoral arteries, every three years
should be considered.
Class Level References
IIa C Loftus et al. (1999),242 Ravn et
al. (2008)238
Recommendation 49
Antiplatelet therapy or anticoagulation and statins are
recommended long term to reduce cardiovascular events
following acute limb ischaemia revascularisation caused by
native artery thrombosis, thrombosis of a popliteal artery
aneurysm, or failure of previous revascularisation.
Class Level References
I A Mangiafico and Mangiafico
(2011),227 Tomoi et al. (2013),239
Paraskevas et al. (2013),230
Aboyans et al. (2018),4 Venermo
et al. (2017),240 Proietti et al.
(2017),241 Heart Protection
Study Collaborative Group
(2002)2295. REGISTRIES AND QUALITY IMPROVEMENT
5.1. Variables to include in registries
Vascular registries aim tomonitor outcomes, improve quality,
and form the basis for research. Some registries cover all
types of open and endovascular procedures; others are
focused on specific operations, such as abdominal aortic
aneurysm repair and carotid endarterectomy. The first in-
ternational collaboration of vascular registries,Vascunet, was
created in 1997. It focused on harmonising variables and
outcomes suitable for quality improvement projects.243,244
One of the first Vascunet reports described great interna-
tional variations in treating > 32 000 patients with infrain-
guinal bypass for PAD, but, unfortunately, those treated for
ALI were excluded from this investigation.245 However, a later
publication on 1 471 patients treated for PA in eight countries
reported specifically on thosewho had been treated for ALI.58
The proportion of PAs treated as an emergency (including just
a few ruptures) varied from 0% in Iceland to 74% in Hungary.
5.1.1. Acute limb ischaemia in existing vascular registries.
In 2014 Vascunet joined with the recently founded North
American Society for Vascular Surgery Vascular Quality
Initiative (VQI) and created the International Consortium of
Vascular Registries.246 Similar to the Vascunet, the focus of the
VQI has been on PAD, but it has also reported on the pro-
portion of patients treated for ALI. In a report on 15 338
bypass procedures and 33 926 endovascular procedures, 14%
and 10%, respectively, were on patients admitted with ALI.247
Mortality and major amputation rates did not differ between
regions, either after open or endovascular surgery, but there
were significant differences in myocardial infarction. Another
paper reported that 9% of those who underwent major
amputation in 2013 e 2015, were admitted with ALI.248 They
also reported a higher proportion of above knee amputations
(57%) in those who had an amputation after ALI than in those
who had an amputation for other reasons (43%).
Amputation was also the focus of an extended Vascunet
collaboration in 2010 e 2014, which showed great inter-
national variation in incidence, by a factor of six, between
participating countries.249 Amputations for acute throm-
bosis and embolus were included in this investigation.
Many registries still do not capture specific data to monitor
and improve outcomes after ALI. However, in the Vascunet
study on PA, the authors suggested that vascular registries
shouldcapture the followingdata:diameterof thePA; thrombus
in the aneurysmal sac, indication for repair; number of runoff
vessels; thrombolysis; and open surgical approach (medial or
posterior).250 They also suggested reporting patency, amputa-
tion, and symptoms at 30 days and one year after surgery.
5.1.2. Suggested variables for future registries. One way of
improving registry data collection is to reach consensus
through a Delphi process, and two such processes took
place in 2018. The first paper identified 79 recommended
variables to be included in registries on all patients with
PAD,251 including obvious variables such as survival and
amputation. The second Delphi process focused on ALI: 23
variables were recommended for the minimum core data
ESVS 2020 Management Guidelines for Acute Limb Ischaemia 203set (Level 1). An additional 12 more specific variables, and
more detailed information on the previously mentioned 23
variables, were suggested for registries that are capable of
capturing more data (Level 2 e 3).252Recommendation 52
It is recommended that outcomes after treatment of acute
limb ischaemia should be monitored in vascular registries,
using variables that have been developed specifically for
this group of patients.
Class Level References
I C Behrendt et al. (2019)2525.2. Claims data or administrative data
An alternative to prospectively collected vascular registry data
is to use existing health insurance claims or statutory hospital
episode statistics.240 While registry data are usually collected
specifically for comparative audit driving quality improve-
ment, and for research, claims data consist of heterogeneous
information used for reimbursement or administration.
Nevertheless, claims data are often sufficiently valid for major
events, such as death or amputation. An important advantage
is that claims data may have high external validity (i.e., few
missing cases) when compared with some registry data with
lower quality. In addition, there is usually complete follow up
until death, and subsequent hospital episodes can be
captured.253 Furthermore, data collection using claims is not
limited to a single society or medical specialty, but includes all
healthcare providers.There are also limitations, such as lack of
anatomical data or patient reported outcomes. As many
countries and regions lack a high quality vascular registry for
quality improvement of treating patients with ALI, the use of
claims data is an alternative that should be considered.
5.3. Quality improvement projects
Improving outcomes after ALI has not yet been the focus of
quality improvement in any of the registries. Simply by
monitoring outcomes over time, and comparing units, re-
gions, and nations, results are likely to improve. It is
important, for instance, to monitor mortality, amputation,
level of amputation, and fasciotomy rates.
It is also possible that specific factors are associated with
outcome, such as delay frompresentation to revascularisation,
or treatment at a centre with both open and endovascular
capability. If such factors can be shown to be independently
associated with the outcome in prospective registry data
collection, they can be used in the future as quality improve-
ment targets. Vascular societies should develop benchmarks
for treatment outcomes of patients with ALI.Recommendation 53
For patients treated for acute limb ischaemia, quality
improvement projects and benchmark indicators should be
considered.
Class Level References
IIa C Behrendt et al. (2019),252
Behrendt et al. (2018)249,2516. ACUTE AORTIC OCCLUSION WITH BILATERAL LOWER
LIMB ISCHAEMIA
6.1. Aetiology and diagnosis
AAO is an immediately life threatening condition. It can be
caused by large saddle emboli from the heart (usually a
complication of acute myocardial infarction); by thrombosis
of an atherosclerotic or aneurysmal aorta (or both the
common iliac arteries), sometimes secondary to thrombo-
philia or low cardiac output, or by an acute occlusion of a
previously inserted graft or stent graft. It is a rare condition
(see below), which also results in a lack of robust data to
guide management. The condition remains a true challenge,
even for an experienced clinician.
Aortic dissection may result in AAO, most often a result
of compression of the true lumen. This condition is covered
by the ESVS Management of Descending Thoracic Aorta
Diseases: Clinical Practice Guidelines,6 and will not be dis-
cussed in the present Guidelines.
Diagnosis of AAO is sometimes difficult, in particular
when the patient presents with bilateral lower limb paral-
ysis,254 and delay is associated with poor outcome.255 Most
publications consist of relatively small case series, and in a
recent paper the authors concluded that outcome had not
improved over time.256
6.2. Treatment
One of the explanations for why treatment is not always
successful, even if performed in a timely way, is that the IRI
is so massive when both lower limbs are affected by
ALI.198,257 AAO is a more serious threat to life than to limb.
For further reading on IRI, see section 3.9.5.
In a nationwide study from Sweden, 715 patients were
operated on over a 21 year period for AAO, resulting in an
incidence of 3.8 per million person years.258,259 In situ
thrombosis dominated (64%), followed by saddle embolus
(21%) and occluded grafts/stent grafts (15%). Interesting
time trends were reported: an increase of the number of
occluded grafts/stent grafts; a decrease of in situ throm-
bosis; and a stable proportion of saddle embolus. Overall,
within 30 days the amputation risk was 9% and mortality
20%, but results improved over time according to this study
(mortality decreased from 25% to 15%).
The rate of surgical revascularisation is dependent on the
aetiology. In the Swedish study, 32% underwent thrombo-
embolectomy, 22% CDT, 19% axillobifemoral bypass, and
18% aortobi-iliac or -bifemoral bypass.258 There are no
comparative studies on which revascularisation method is
preferable in which situation. The decision making should
take into account aetiology, comorbidities, resources, and
experience, and is based on standard vascular surgical
principles.6.3. Effect of increased use of endovascular aneurysm
repair
The increased use of endovascular aneurysm repair (EVAR)
has resulted in an increased risk of aortic occlusion due to
204 Martin Björck et al.stent graft thrombosis. The EVAR-I trial reported a 3 e 4
times higher rate of graft related complications after
endovascular aneurysm repair compared with open aortic
surgery.260 Newer generations of stent grafts may be more
flexible and have more kink resistant limbs261 which may
reduce the incidence of EVAR graft limb occlusion. For more
details regarding aortic or iliac occlusions after aortic sur-
gery, and recommendations on how to prevent this
complication, please consult the ESVS 2019 Clinical Practice
Guidelines on the Management of Abdominal Aorto-iliac
Artery Aneurysms, in particular section 6.3.2.7Recommendation 54
For patients with acute limb ischaemia secondary to acute
aortic occlusion, it is recommended that revascularisation
is performed urgently.
Class Level References
I C Kaschwich et al. (2017),257
Beyersdorf and Schlensak
(2009),198 Grip et al. (2019)258
Recommendation 55
For patients who have undergone revascularisation for acute
limb ischaemia secondary to acute aortic occlusion, close
collaboration is recommended with anaesthetists and
intensivists to reduce the complications of ischaemia
reperfusion injury.
Class Level References
I C Kaschwich et al. (2017),257
Beyersdorf and Schlensak
(2009)1987. DIAGNOSIS AND TREATMENT OF ACUTE UPPER LIMB
ISCHAEMIA
Acute upper limb ischaemia is not as common as acute
lower limb ischaemia.262,263 There are a number of other
differences: the ischaemia is more likely to be embolic and
it is less likely to be limb threatening.264,265 It is also less
likely to be immediately life threatening than lower limb
ischaemia, although late mortality rates are high owing to
the underlying disease and comorbidities.266
The tissue effects of ischaemia are similar to the lower
limb, but management and treatment cannot be evidence
based, as there are no RCTs and few large cohort studies.
There are a number of core principles. Patients should be
treated by vascular surgeons with expertise, in units where
there is access to a full range of vascular and endovascular
therapeutic options.
Acute treatment is similar for upper and lower limb
ischaemia: systemic AC; intravenous fluids; oxygen; and
medical optimisation (e.g., management of AF).Cardiac embolism is the most common cause of acute
upper limb ischaemia; thrombosis is less often the aetiology
(17% in a large UK cohort).267 There are a number of other
rare causes, such as distal thrombosis due to thrombophilia,
ischaemia due to the complications of thoracic outlet syn-
drome, arteritis, stenosis secondary to radiation treatment,
and subclavian aneurysm. These guidelines focus on treat-
ment of emboli to the upper limb.7.1. Diagnostic strategy
The diagnosis is clinical and the level of occlusion can be
determined by palpation of pulses. Confirmation is by
arterial imaging with DUS or CTA. Arterial imaging may not
be necessary before intervention for every patient with
acute upper limb ischaemia. If the patient has a typical
cardiac embolus (AF, short history, and normal arterial
pulses elsewhere), it may be reasonable to proceed to
treatment immediately if the limb is immediately threat-
ened and if the axillary artery pulse in the upper arm is
easily palpable (i.e., there is inflow for a brachial embo-
lectomy). If the ischaemia is not typically embolic (e.g., in a
young patient when thoracic outlet syndrome or a cervical
rib is suspected; thrombosis associated with radiotherapy;
subclavian aneurysm; or if there is a suspicion of aortic
dissection) or the axillary pulse is not palpable, imaging of
the proximal upper limb vessels is mandatory before
treatment (in most cases a CTA). Blind embolectomy in this
situation may not improve the blood flow to the hand and
may simply make the ischaemia worse. If the artery is
patent it is important to perform an elevation test with DUS
or DSA, to verify a thoracic outlet syndrome mechanism, if
present.7.2. Surgical decision making
Some patients with upper limb ischaemia appear to have no
immediate threat to their limb, (no motor or sensory loss,
no muscle tenderness, audible arterial signals at the wrist
on Doppler; Rutherford grade IIa) and conservative treat-
ment with AC alone may be appropriate. The risk is that
although the limb may remain viable, the patient may suffer
from forearm claudication, which makes use of the arm
painful and affects quality of life. As for lower limb
ischaemia, there should be a discussion about options,
individualised to risks and benefits for each patient. Factors
that may be taken into account are whether the dominant
hand is affected, the age and condition of the patient, the
patient’s occupation, and the severity of the ischaemia. If
the decision is made to treat upper limb ischaemia
conservatively with AC alone, the arm should be reviewed
regularly over the next few days to ensure it does not
deteriorate. AC alone has been suggested as primary ther-
apy,268 but a review of 23 studies suggested that poor
functional outcomes were reported more often after a
conservative approach.269
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Most patients with upper limb ischaemia are treated
surgically by brachial embolectomy (Fig. 12); bypass sur-
gery is seldom required acutely. The default should be
surgery under local anaesthesia, with an anaesthetist
present, and with the option for intravenous sedation and
resuscitation, if required. Technical details are discussed
elsewhere, but controversies include which incision to use
in the skin; whether the brachial bifurcation needs formal
dissection,270 and whether both forearm arteries need re-
opening; transverse or longitudinal arteriotomy in the
brachial artery; size of Fogarty catheter; and method of
arterial repair. In a review of 100 patients, it was sug-
gested that intra-operative angiography after embolec-
tomy may reduce the risk of re-occlusion.271 Alternatively,
the ischaemic hand can be placed in a sterile clear plastic
bag during the surgery, and if embolectomy restores
visible perfusion and a palpable wrist pulse, check angi-
ography may not be needed. Long term functional results
after embolectomy272 and surgical bypass267 are
reassuring.7.4. Endovascular surgery
Endovascular treatments such as percutaneous throm-
bectomy,273 aspiration thrombectomy,274 or CDT155 have
been used for acute upper limb ischaemia, but only case
reports exist to describe their benefits and complications.
CDT through a femoral approach, with a catheter in the
aortic arch, is associated with the risk of cranial vessel
embolism,275 but it can also be performed with a brachial
approach, minimising that risk. Clots may also detach and
pass cranially from the proximal end of the occlusion, a
phenomenon known as whirlpool embolism.276 Primary
distal thrombosis of the hand (or residual distal ischaemiaFigure 12. Thrombectomy of the brachial artery using a Fogarty
catheter.after embolectomy) may benefit from CDT or intravenous
prostaglandin therapy.7.5. Compartment syndrome and fasciotomy
After successful reperfusion of the upper limb, CS is a rare
complication. However, if it occurs it can still result in long
term damage by contracture, or even limb loss. Prophylactic
fasciotomy is seldom indicated, but if the arm has been
ischaemic for many hours and swells considerably after
successful embolectomy, fasciotomy is indicated. If it is
indicated, volar fasciotomy is suggested, but concurrent
dorsal fasciotomy is also recomended by some authors
(Fig. 13).277 Advice and assistance from orthopaedic, hand,
or plastic surgeons may be necessary.Figure 13. (A, B) Fasciotomies of the forearm. Surgical
approach for (A) anterior and (B) posterior fasciotomies. (C)
Fasciotomies of the superficial posterior and deep posterior
compartments (red arrow, 1), fasciotomies of the anterior and
lateral compartments (red arrow, 2). Reproduced with permis-
sion from Ricco et al.202
Recommendation 56
For patients with acute ischaemia of the upper limb, pre-
operative imaging is recommended, unless embolic
occlusion is obvious, the limb is immediately threatened,
and axillary or proximal brachial pulses are palpable.
Class Level References
I C Consensus
Recommendation 57
For a patient with acute ischaemia of the upper limb,
conservative treatment with anticoagulation alone is not
recommended if the arm is threatened, or if limb function
is important to quality of life.
Class Level References
III C Turner et al. (2010),268 Wong et
al. (2015)269
Table 11. Aetiology of acute limb ischaemia and approximate
relative frequencies in children278e282
Aetiology Frequency
(%)
Neonates and infants
Intra-uterine compression <1
Inborn coagulation disorders 1e2
Iatrogenic 85e95
Umbilical artery catheterisation
Femoral artery catheterisation
Embolic 1e2
Great vessel malformations
Large cardiac defects
Idiopathic 1e2
Young children
Iatrogenic 20e50
Femoral artery catheterisation
Traumatic 50e80
Penetrating trauma
Blunt trauma (including the
pulseless pink hand syndrome)
Idiopathic <1
206 Martin Björck et al.8. ACUTE LIMB ISCHAEMIA IN CHILDREN
8.1. Epidemiology
ALI in children is a rare but potentially catastrophic event
associated with mortality, limb loss, and permanent long
term disability. The entity is observed in 26 e 85 of every
100 000 paediatric admissions,278,279 and in < 1% of
paediatric trauma.280,281 In most instances, ischaemia is
iatrogenic and results from thrombosis secondary to um-
bilical or femoral artery catheterisation, especially in ne-
onates and young infants.278 Symptomatic thrombotic
complications occur in 0.2% of neonates in intensive care
units. However, asymptomatic catheter related arterial
thrombosis is much more common, ranging from 3% to
90%.282 Other causes of ALI relate to penetrating or blunt
trauma, cardiogenic embolisation in infants with congen-
ital heart or great vessel malformations, inborn coagula-
tion disorders, or intra-uterine extrinsic compression
(Table 11).8.2. Diagnosis
Clinical presentation of ALI in neonates and small children
may be less obvious than in the adult population. Thus, a
high index of suspicion is necessary, especially when
arterial catheterisation was performed. This can be
explained by limited capacity to verbalise complaints and
also by smaller limbs and less developed muscles which
are more tolerant of hypoxia. Furthermore, collateralisa-
tion may be improved and develops rapidly early in
life.283,284 The most common presentation is cyanosis and
delayed capillary refill. Necrotic changes are less frequent.
In a large cohort study based on registry claims data, in-
fants, vs. older children, had a lower risk of upper ex-
tremity ALI, higher mortality, and were more often treated
without intervention.278 Several publications have sug-
gested that DUS is a useful to guide vascular puncture, to
minimise the incidence of catheter related arterial
thrombosis, and also for the early diagnosis of thrombotic
complications.285e2878.3. Treatment options and outcome
Conservative management with systemic heparinisation has
been the mainstay of ALI treatment in children, mostly
based on expert opinion and small case series, as literature
is scarce. AC alone appears to be a relatively safe earlystrategy in the majority of cases, allowing partial or com-
plete resolution of thrombus, development of collaterals,
and recovery of limb perfusion283,284,288e290 at the price of
a small risk of bleeding complications (3% in one investi-
gation).283 Both UFH and LMWH may be used as antico-
agulants. For UFH, a bolus of 75 IU/kg followed by perfusion
at 28 IU/kg/hour for infants < 1 year of age and 20 IU/kg/
hour for older children is generally used, adjusted to an
APTT of 55 e 85 seconds.291 Succesful treatment by sys-
temic thrombolysis is also reported, although there is a risk
of intracranial bleeding, especially in preterm infants.292e
294 Long term outcomes of conservative management
have also been evaluated, suggesting that 15% of affected
children will have either intermittent claudication or limb
discrepancy as a result of impaired growth later in
life.283,295,296
Up to 17% of children affected by ALI were treated with
revascularisation in a population based study, they were
older than those treated conservatively, and the aetiology
was more often traumatic.278 Infants and young children
present significant technical challenges for revascularisation
and the surgical outcomes are worse than those of older
children.289,297 Infants, in particular, do not have improved
outcomes after surgery, when compared with those treated
conservatively.278
There is no evidence to suggest that the same concepts
of intervention for ALI used for the adult population
should apply to children. A few reports have been pub-
lished on the use of systemic or CDT, thrombo-aspiration,
or surgical thrombectomy. These are mostly small series
from single centres, suffering from publication bias, and
they do not support a generalised first line approach for
intervention. However, endovascular treatment does
appear to be a safe strategy, and may be used selectively
in the most severe limb threatening cases.282 In a recent
Recommendation 58
For infants and children younger than 2 years of age with
acute limb ischaemia, initial conservative management
with heparin is recommended.
Class Level References
I C Lim et al. (2018),278 Rizzi et al.
(2018),288 Sadat et al.
(2015),289 Lin et al. (2001)297
Recommendation 59
For infants and children undergoing femoral catheterisation,
ultrasound guided puncture and post-procedural ultrasound
examination should be considered.
Class Level References
IIa C Alexander et al. (2016),285
Kulkarni and Naidu (2006),286
Knirsch et al. (2013)287
Recommendation 60
For infants and children with acute limb ischaemia without
improvement after conservative therapy with heparin,
thrombolysis, or open surgical revascularisation may be
considered.
Class Level References
IIb C Rizzi et al. (2016),288 Sadat et al.
(2015),289 Kayssi et al.
(2014),283 Matos et al.
(2012),284 Downey et al.
(2013),290 Wang et al. (2018)296
Recommendation 61
In school children with a supracondylar humeral fracture
and a pulseless, perfused hand, watchful waiting may be
considered an alternative to immediate surgical exploration.
Class Level References
IIb C Griffin et al. (2008)299
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database including nearly 1 600 children with ALI, no
differences were found between conservative manage-
ment and intervention regarding mortality (4% overall),
amputation (< 2% overall), or length of hospital stay.
Owing to the administrative nature of the database,
severity of ischaemia could not be determined and se-
lection bias may be present. Nonetheless, these out-
comes compare favourably to the adult population.278
Similarly, a recent systematic review including all man-
agement strategies suggests that limb salvage is 88%
(95% CI 1% e 31%) and overall mortality 7% (95% CI 2%
e 14%).298
From a case series of 25 children aged < 12 months,
with ALI mainly caused by iatrogenic injuries following
arterial cannulation, the following was reported:296 in 88%
the lower extremity was affected, and the diagnosis was
obtained by missing Doppler signals (64%) or cyanosis of
the extremity (60%). Whenever possible (80%), primary
therapy consisted of AC; two patients were treated by
thrombolysis. Three died within 30 days, independently of
ALI. One patient needed an above knee amputation.
Functional long term results were excellent, which shows
that ALI can be treated successfully with AC. As there are
no RCTs, no direct comparison can be made regarding
conservative management and intervention in paediatric
patients. However, a first line conservative management
seems justified, with the possible exception of older chil-
dren with traumatic injuries. No evidence supports the use
of one single intervention strategy over another, when
considered necessary.
As ALI in small children (aged < 2 years) is very un-
common, and as blood vessels are small, a multidisci-
plinary approach is warranted. Plastic surgeons and hand
surgeons with experience of microsurgery, as well as
paediatric surgeons, may be helpful when open surgery is
necessary.
In school children, supracondylar fracture of the hu-
merus is a common cause of upper extremity ALI. This
entity results from brachial artery injury, and the majority
of cases resolve after closed reduction and stabilisation of
the fracture. In a systematic review, an overall incidence of
vascular compromise in 3% to 14% after supracondylar
fractures was identified, which persisted after reduction
and stabilisation in 28%.299 When severe signs of ALI are
present, exploration is advisable. However, some limbs
remain pulseless despite apparent perfusion of the hand.
This is often referred to as the “pulseless pink hand”, and
management is more debatable. Many authors recom-
mend watchful waiting, as symptoms usually resolve and
the pulse returns within one week. Exploration is reserved
for patients who develop additional signs of ischaemia, or
for those without improvement after one week.299 When
considered necessary, exploration with release of brachial
artery entrapment at the fracture site, primary arterial
repair, venous patch angioplasty, or venous interposition
grafts appear to be the preferred surgical options.3009. UNRESOLVED ISSUES AND FUTURE RESEARCH
9.1. Diagnosis
The ESVS ALI guidelines recommend that a diagnosis of ALI
should be made primarily on clinical grounds (typical
symptoms and signs). Although most patients with ALI
present with a typical constellation of symptoms and signs,
it is unknown how frequently the diagnosis is delayed as a
result of inexperienced assessment (patients usually initially
present to non-vascular specialists) or atypical pre-
sentations. Future research should be considered in pa-
tients presenting with suspected ALI to establish the
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clinical symptoms and signs and biomarkers (both novel and
those used routinely). The standard for the future diagnosis
of ALI in these studies would be CTA.
Theoretically, the role of emergency CTA in a patient with
ALI, with or without motor deficit, needs to be evaluated in
an adequately powered multicentre RCT. However, it is
possible that the window of opportunity has closed, as this
has already become a routine in many countries.
9.2. Classification and prognosis
It is important to be able to classify patients presenting with
ALI. It aids clinical decision making and allows comparisons
to be made for the purposes of clinical audit and inter-
ventional studies. The most widespread scheme in general
clinical use for patients with ALI is the Rutherford system.2
This was published some years ago and its development
would not stand up to modern rigorous methodologies.
Although it has been in widespread use for over 20 years, its
clinical performance as a tool for classification (including
reliability/repeatability, etc.) and its ability to provide a
prognosis have yet to be established. It would be valuable
to assess its utility as a clinical classification tool. Currently,
no biomarkers (e.g., serum CK or myoglobin) are available
to identify patients who require primary amputation.
Further research might help to identify patients who have a
non-salvageable limb, or in whom attempts at revascular-
isation may be futile (and/or harmful).
9.3. Interventions
AC with intravenous UFH has become the mainstay of initial
therapy for patients presenting with ALI, despite the fact
that a small RCT published in 1991 reported no benefit and
more bleeding complications with this practice.61 It is
difficult to be certain whether this intervention is effective
in improving outcomes and may never be tested in a new
trial, unless an alternative with a rapid onset (and offset) of
action were to be developed. There are some suggestions
that adjunctive therapy with prostacyclin analogues may
improve outcomes, but the trials and evidence are weak
and more robust data in the form of RCTs would help
confirm these observations.
The studies comparing surgery with CDT were reported in
the 1990s. Technologies have changed significantly and the
population of patients with ALI has also changed (older
patients with a greater number of comorbidities and fewer
presenting with ALI secondary to embolism). It is difficult to
be certain how relevant these RCTs are to contemporary
clinical practice. Interestingly, in many countries surgery has
become the standard of care, whereas in others CDT is the
primary intervention. Ideally, these RCTs could be repeated
to inform the optimal revascularisation technique for ALI.
This work is closely linked to improvement of the classifi-
cation system (see section 9.2).
As the RCTs of CDT and surgery were reported in the
1990s a variety of additional endovascular techniques
(including ultrasound, aspiration, and mechanicalthrombectomy) have come to market and are in regular
clinical use. Unfortunately, few of these techniques have
been tested in appropriately powered trials and their clin-
ical and cost effectiveness remain to be fully established
when compared with standard interventions. Those that
were tested have failed to demonstrate that they are as
good as standard endovascular therapies. It is the view of
the ESVS guideline team that patients receiving modern
technologies should be enrolled in trials or clinical registries
to monitor safety and effectiveness.
A variety of thrombolytic drugs and techniques are avail-
able. Different infusion catheters and lytic dosing regimens
exist, including the use of pharmacological (e.g., abciximab)
and mechanical adjuncts. Each technique has its merits, but
none has been proven to be superior. rtPA and urokinase
remain the agents of choice, but newer agents (reteplase and
tenecteplase) have become available (and others are also
being considered, e.g., plasmin) and should be tested within
appropriately designed trials. The search for the ideal
thrombolytic drug continues and novel agents should be
tested within appropriately powered clinical trials.
Patients who present with ALI due to thrombosis and or
embolisation from PA present a unique challenge with a
high rate of limb loss and disability. It is recommended that
surgery is the primary revascularisation technique for this
condition. However, as endovascular techniques become
more sophisticated, and algorithms for endovascular in-
terventions such as popliteal stent grafting and CDT become
available in these patients, their role requires elucidation in
properly constructed clinical trials.
An important subgroup of patients are those who pre-
sent with acute onset claudication. Data from the 1990s
suggested that the prognosis was good with conservative
treatment and that complications were not infrequent.
Those old data are the basis of the negative recommen-
dation in these guidelines, advising against treating these
patients invasively. This issue needs to be re-addressed in a
contemporary study, preferably an RCT, as endovascular
therapy has developed.
Controlled limb reperfusion for the prevention of IRI has
been extensively investigated over the last 20 years. Initial
studies concluded that it may reduce the local manifesta-
tions of the post-ischaemic syndrome after prolonged
ischaemia in salvaged limbs.198 However, in a recent RCT no
difference was found in amputation free survival between
conventional treatment of ALI and controlled limb reper-
fusion.199 Hypothermic, initially oxygen free controlled limb
reperfusion with ECMO was used in a study of patients with
ALI, which suggested that this new treatment might limit
complications and mortality, but the evidence was not
conclusive.185 Further prospective, RCTs are needed to
evaluate this hypothesis.9.4. Complications
Revascularisation of the ischaemic limb, whether by endo-
vascular methods or open surgery, is associated with a
number of key complications. These include, most notably,
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complications. Efforts have been made to reduce the inci-
dence of minor and major haemorrhage during the
administration of thrombolysis. The use of systemic hep-
arinisation and longer duration of lysis are associated with
increased bleeding risk and should be avoided. Minor
bleeding during thrombolysis is common. Standard ap-
proaches to managing access site bleeding have been to
apply compression, adjust the dose of (or stop) the lytic
agent, and to increase the sheath size. Innovative systemic
therapies to manage minor access site bleeding include the
use of desmopressin and these should be evaluated in trials.
CS is associated with significant morbidity and should be
prevented by pre-emptive fasciotomy in high risk patients or
diagnosed and managed as soon as it develops. Methods to
identify patients at high risk of developing CS would be
valuable in clinical practice. At present, the reliability of
diagnostic techniques, such as the measurement of intra-
compartmental pressures, is low. The predictive value of
different biomarkers needs to be evaluated. Several different
methods of wound management after fasciotomy and ap-
proaches to delayed wound closure have been described.
There is a need for comparative studies to be able to issue
recommendations in this important clinical situation.
The development of perisheath thrombosis should be
avoided whenever possible. Systemic heparinisation results in
an increased bleeding risk; however, it is uncertain whether
the local administration of UFH through the access site sheath
is superior to regular flushing with crystalloid solutions, or no
flushing at all. This important detail needs to be investigated.
ALI is associated with a stubbornly high rate of systemic
complications (including renal failure) and death, even after
successful revascularisation. Strategies to reduce these
complications would be welcome. The best approach to
address these problems remains to be determined,
including the optimal level of care. Expert interdisciplinary
consensus methodology to develop novel interventions and
quality improvement programmes could hold the key to
improved outcomes.9.5. Outcomes
Future research in ALI could be enhanced if it was possible to
standardise the reporting of studies and outcomes were
shown to be highly relevant to patients, healthcare pro-
fessionals, and healthcare commissioners. ALI is associated
with a significant mortality risk and a high rate of subsequent
complications. Reporting standard guidelines in PAD were
developed with a focus on chronic rather than acute disease.
No core outcome set for patients presenting with ALI exist
and there are no guidelines on how best to report studies on
patients with ALI (reporting standards). Future work should
focus on developing both a core outcome set and a core
reporting set for patients with ALI. A core reporting set for
use in registries has been developed through international
and interdisciplinary collaboration, as a spin off effect of
developing these Guidelines,252 but these need to be eval-
uated in future quality improvement projects. Patientreported outcome measures are important tools to assess
the impact of interventions and their delivery on patients. A
variety of generic quality of life tools exist for patients with
vascular disease; however, none exists specifically for pa-
tients with ALI, and this is a clear gap that should be filled.
9.6. Long term therapy
Patients who develop ALI are at increased risk of recurrent
ischaemic events. The standard management strategy
following limb revascularisation has been to anticoagulate
patients and manage the underlying cause (e.g., AF). The
duration and dosage of AC in patients in whom no under-
lying cause has been found is a matter of debate and re-
quires further research. It remains to be established what
role antiplatelets and DOACs have compared with standard
alternatives (heparins and coumadins) and, specifically,
whether they reduce recurrent ALI and improve limb sur-
vival. The role of antiplatelet therapy vs. AC, and the com-
bination of both therapies, needs to be evaluated in this
specific patient group.
Around 25% of patients presenting with PAD (and ALI)
have evidence of a thrombophilia. It is unclear whether the
outcome of these patients differs and whether they require
alternative management strategies to improve outcomes
and prevent ALI recurrence.
It remains to be determined whether new drug regimens
could be beneficial, such as proprotein convertase subtilisin/
kexin type 9 (PCSK-9), rivaroxaban vascular dose, and so on.
9.7. Standards
Standard setting and benchmarking would be valuable in
ALI. These would enable enhanced assessment and approval
of new interventions for the management of patients with
ALI, and appropriate comparative audits in routinely
collected data. A more precise characterisation of the de-
gree of ischaemia (see section 8.2) could be used to define
the maximum time interval from diagnosis to treatment.
Quality improvement projects in other areas of PAD
management have had a beneficial effect. Attempts should
be made to design similar projects to improve the outcomes
of patients suffering from ALI.
In summary, despite the identification of 28 RCTs from the
literature, there is a great need for future research to enable
improvement of the management of patients with ALI. Most
of these unresolved issues require multicentre collaboration.
10. PLAIN ENGLISH SUMMARY
Acute limb ischaemia (ALI) is a sudden reduction in the
arterial blood supply to the arm or leg. There are two main
causes: thrombosis as a result of blood clot developing
within the artery, usually at a site of previous narrowing in
people with hardening of the arteries; and embolus, where
blood clot develops elsewhere in the body (usually the
heart), detaches and passes through the arterial circulation
to lodge in one of the main blood vessels to a limb. ALI is a
serious condition that threatens both the limb itself and the
life of the patient. Failure to restore the arterial circulation
210 Martin Björck et al.often results in limb amputation and can cause death. ALI is
more common and more serious in the leg than in the arm.
An international group of specialists has examined the
research that has been published on ALI and has summar-
ised the evidence about the best methods of managing this
condition. This guideline has been produced to help doctors
provide the best care for ALI.
Firstly, it is important that all doctors recognise the signs
and symptoms of ALI characterised by the six Ps: painful,
pale, pulseless, paraesthesia (numbness), paralysed, and
perishingly cold. Secondly, doctors need be able to assess
how bad the ALI is. If it causes numbness or paralysis of the
limb, it is very severe and the limb may be impossible to
save if untreated within around six hours.
Once the diagnosis of ALI has been made, the guideline
group has recommended that patients should be treated by
experts (usually a vascular specialist) in a hospital where
assessment and treatment is available 24/7. Patients may
need to be transferred urgently to a specialist hospital.
After assessment, the group recommends patients are
treated by experts who are able to use all possible treat-
ments that are available. Until 25 years ago the only
possible treatment for ALI was surgery. Now there are a
variety of clot busting drugs and new methods of aspirating
blood clots percutaneously, without needing an operation.
The guideline group has looked at all the scientific
research on different methods of treating ALI. Both surgical
and non-surgical treatments, such as clot busting drugs, are
effective but with subtly different outcomes depending on
individual patients. The group has made recommendations
about how to use the different treatments to obtain the
best outcomes. The best results seem to be achieved in
hospitals used to dealing with patients with ALI, and
familiar with all the different methods available, choosing
the method most suitable for each individual patient.
It is hoped these guidelineswill be used by doctors treating
patients with ALI to give them the best care, thus giving them
the best chance for full recovery without complications.
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